var title_f8_4_8256="Contact lens-associated fungal keratitis";
var content_f8_4_8256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Contact lens-associated fungal keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 175px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fungal keratitis in a 30-year-old female who wore daily disposable soft contact lenses.",
"    <br>",
"     (A) The central corneal infiltrate progressed dispite intensive antifungal therapy.",
"     <br>",
"      (B) A central 7 mm corneal transplant (penetrating keratoplasty) was performed 8 days after diagnosis to control the fungal infection.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Jurkunas U, Behlau I, Colby K. Fungal keratitis: Changing pathogens and risk factors. Cornea 2009; 28:638. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8256=[""].join("\n");
var outline_f8_4_8256=null;
var title_f8_4_8257="Common precursors of lymphocytes";
var content_f8_4_8257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T and B cells develop from a common precursor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 472px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The development of distinct &alpha;&beta; and &gamma;&delta; T cell lineages, B1 and B2 subgroups, NK cells and the lymphoid (or follicular) dendritic cells is depicted here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Wraith, D. Immunologic tolerance. In: Immunology, 6th Ed, Roitt, I, Brostoff, J, Male, D (Eds), Mosby, London 2001. p.193",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8257=[""].join("\n");
var outline_f8_4_8257=null;
var title_f8_4_8258="Interactive diabetes case 11: A 34-year old pregnant woman with type 2 diabetes";
var content_f8_4_8258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 11: A 34-year old pregnant woman with type 2 diabetes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8258/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8258/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8258/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/4/8258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 34-year old Hispanic woman returns to see you after an interval of two years for management of diabetes during pregnancy. The patient was diagnosed with diabetes at age 17. She was treated with oral agents for several years and switched to insulin at age 24. Metabolic control has been poor, with A1C values repeatedly in the 12 to 14 percent range. The patient has had microalbuminuria for at least one year. She had not been following a diet for many years, although she reduced her caloric intake a few months ago in anticipation of pregnancy, and is sedentary. She intermittently has polyuria, polydipsia, and nocturia. Her last menstrual period was 14 weeks ago. Her home pregnancy test was positive one week ago. She performs fingerstick blood glucose testing intermittently. You download the memory on her glucometer. The printout indicates a 14-day average glucose value of 229",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (12.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with average values of 119 before breakfast, 175 before lunch, 284 before supper, and 244 at bedtime. Her most recent dilated eye exam, 11 months ago, revealed moderate non-proliferative retinopathy with scattered microaneurysms and exudates. Physical examination reveals a blood pressure of",
"    <span class=\"nowrap\">",
"     118/68,",
"    </span>",
"    weight of 176 lbs (80 kgs, unchanged from the previous visit), and body mass index of 31.2. Peripheral pulses are present in both feet. Vibratory sensation is reduced at the great toes and medial malleoli, light touch is reduced to the mid-calf level, and deep tendon reflexes are absent at the ankles but present at the knees. Laboratory studies include the following: BUN 19",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    creatinine 0.9",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    urine",
"    <span class=\"nowrap\">",
"     microalbumin/creatinine",
"    </span>",
"    ratio 86.3",
"    <span class=\"nowrap\">",
"     mg/gm",
"    </span>",
"    (normal &lt;30), A1C 8.6 percent. The quantitative HCG test is positive at 48,418",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    The patient is on an insulin regimen of NPH (human) 20 units and regular (human) 5 units before breakfast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    5 units before supper and NPH 15 units at bedtime.",
"   </p>",
"   <p>",
"    What is your assessment?",
"   </p>",
"   <p>",
"    A1- The patient has type 2 diabetes, obesity related, with non-proliferative retinopathy, distal sensory neuropathy and microalbuminuria. She is in poor metabolic control. She needs intensive insulin therapy to decrease the risks of spontaneous abortion, fetal macrosomia, and the neonatal complications of diabetic pregnancy including hypoglycemia, hypocalcemia, hyperbilirubinemia, and polycythemia. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?8/4/8258-a1?source=see_link\">",
"     \"Interactive diabetes case 11: A 34-year old pregnant woman with type 2 diabetes - A1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A2- The patient has type 2 diabetes, obesity related, with non-proliferative retinopathy, distal sensory neuropathy, and microalbuminuria. She is in poor metabolic control. She needs intensive insulin therapy to decrease the risk of congenital malformations, and also the risks of spontaneous abortion, fetal macrosomia, and the neonatal complications of diabetic pregnancy including hypoglycemia, hypocalcemia, hyperbilirubinemia, and polycythemia. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?8/4/8258-a2?source=see_link\">",
"     \"Interactive diabetes case 11: A 34-year old pregnant woman with type 2 diabetes - A2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A3- The patient has type 2 diabetes, obesity related, with non-proliferative retinopathy, distal sensory neuropathy, and microalbuminuria. She is in poor metabolic control. She needs urgent referral for a therapeutic abortion to prevent the maternal and fetal complications of diabetic pregnancy. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?8/4/8258-a3?source=see_link\">",
"     \"Interactive diabetes case 11: A 34-year old pregnant woman with type 2 diabetes - A3\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4180 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-C1C910ED83-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8258=[""].join("\n");
var outline_f8_4_8258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?8/4/8258-a1?source=related_link\">",
"      Interactive diabetes case 11: A 34-year old pregnant woman with type 2 diabetes - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?8/4/8258-a2?source=related_link\">",
"      Interactive diabetes case 11: A 34-year old pregnant woman with type 2 diabetes - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?8/4/8258-a3?source=related_link\">",
"      Interactive diabetes case 11: A 34-year old pregnant woman with type 2 diabetes - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_4_8259="Contents: Pediatric hematology";
var content_f8_4_8259=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric hematology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric hematology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Anemia due to decreased production",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26954\">",
"           Anemia in children due to decreased red blood cell production",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26842\">",
"           Inherited aplastic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/16/21767\">",
"           Macrocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/14/23782\">",
"           Physiology of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33400\">",
"           Shwachman-Diamond syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blood transfusion",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/15/27898\">",
"           A primer of red blood cell antigens and antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11672\">",
"           Administration and complications of red cell transfusion in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6646\">",
"           Complications of therapeutic plasma exchange",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11061\">",
"           Directed (designated) blood donation programs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11769\">",
"           Immunologic blood transfusion reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/23/18808\">",
"           Indications for red blood cell transfusion in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12597\">",
"           Indications for therapeutic plasma exchange",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/41/40601\">",
"           Laboratory testing of donated blood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24665\">",
"           Leukoreduction to prevent complications of blood transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24073\">",
"           Oxygen carriers as alternatives to red cell transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/11/27832\">",
"           Red cell transfusion in infants and children: Selection of blood products",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/35/6710\">",
"           Transfusion-associated graft-versus-host disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bone marrow failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26954\">",
"           Anemia in children due to decreased red blood cell production",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24937\">",
"           Congenital neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/40/17030\">",
"           Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11562\">",
"           Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26842\">",
"           Inherited aplastic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/24/12680\">",
"           Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bone marrow transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/38/26218\">",
"           Donor selection for hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/25/5529\">",
"           Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/51/33590\">",
"           Gene therapy for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11562\">",
"           Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/2/1066\">",
"           Hematopoietic cell transplantation for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30775\">",
"           Hematopoietic cell transplantation in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/36/43591\">",
"           Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/33/34330\">",
"           Specific therapies for sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coagulation disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/4/24650\">",
"           Acquired inhibitors of coagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/59/37818\">",
"           Anticoagulants other than heparin and warfarin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/40/3722\">",
"           Approach to the child with bleeding symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22824\">",
"           Biology and normal function of factor VIII and factor IX",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17049\">",
"           Biology and normal function of von Willebrand factor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/8/44169\">",
"           Classification and pathophysiology of von Willebrand disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1322\">",
"           Clinical manifestations and diagnosis of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24794\">",
"           Clinical presentation and diagnosis of von Willebrand disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/57/14234\">",
"           Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/31/8697\">",
"           Disseminated intravascular coagulation in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/56/36746\">",
"           Factor VIII and factor IX inhibitors in patients with hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/5/33878\">",
"           Genetics of the hemophilias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/40/14986\">",
"           Management of thrombosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/35/27194\">",
"           Overview of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/28/25033\">",
"           Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/56/8073\">",
"           Pathogenesis and etiology of disseminated intravascular coagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/16/14600\">",
"           Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/52/841\">",
"           Protein C deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/55/13176\">",
"           Protein S deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/16/20743\">",
"           Prothrombin gene mutation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/30/14825\">",
"           Screening for inherited thrombophilia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38442\">",
"           Treatment of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43082\">",
"           Treatment of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21866\">",
"           Treatment of von Willebrand disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematopoiesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16890\">",
"           Introduction to recombinant hematopoietic growth factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/34/25129\">",
"           Overview of hematopoiesis and stem cell function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/10/20650\">",
"           Regulation of erythropoiesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6858\">",
"           Regulation of myelopoiesis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemoglobins",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8729\">",
"           Clinical features, diagnosis, and treatment of methemoglobinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42055\">",
"           Genetic disorders of hemoglobin oxygen affinity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/46/4841\">",
"           Genetics and pathogenesis of methemoglobinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/25/42392\">",
"           Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/17/13593\">",
"           Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/11/36025\">",
"           Pathophysiology of alpha thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8058\">",
"           Pathophysiology of beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20858\">",
"           Protection against malaria in the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/29/23001\">",
"           Structure and function of normal human hemoglobins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/38/616\">",
"           Unstable hemoglobin variants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemolytic anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/59/18362\">",
"           Autoimmune hemolytic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/51/19256\">",
"           Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/56/33672\">",
"           Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/50/14121\">",
"           Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/43/17082\">",
"           Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/46/43753\">",
"           Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9194\">",
"           Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/52/3912\">",
"           Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/60/43977\">",
"           Overview of hemolytic anemias in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30535\">",
"           Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/2/20521\">",
"           Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/26/10665\">",
"           Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypoproliferative anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26954\">",
"           Anemia in children due to decreased red blood cell production",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26842\">",
"           Inherited aplastic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Iron metabolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2266\">",
"           Genetics of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/61/33748\">",
"           Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38856\">",
"           Iron overload syndromes other than hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/19/35129\">",
"           Pathophysiology and diagnosis of iron overload syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/37/21082\">",
"           Regulation of iron balance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Laboratory evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/36/4682\">",
"           Clinical use of coagulation tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/29/15834\">",
"           Erythropoietic protoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13689\">",
"           Evaluation of bone marrow aspirate smears",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38313\">",
"           Evaluation of the peripheral blood smear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/5/9305\">",
"           Spiculated cells (echinocytes and acanthocytes) and target cells",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lead poisoning",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/19/20792\">",
"           Anemia of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24585\">",
"           Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Platelet disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/63/25591\">",
"           Causes of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23833\">",
"           Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24295\">",
"           Clinical manifestations and evaluation of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4458\">",
"           Megakaryocyte biology and the production of platelets",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/9/14490\">",
"           Neonatal thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/7/1146\">",
"           Platelet biology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/30/10727\">",
"           Platelet dysfunction in uremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/59/23482\">",
"           Platelet function testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/53/37721\">",
"           Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycythemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24777\">",
"           Diagnostic approach to the patient with polycythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29978\">",
"           Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36968\">",
"           Neonatal polycythemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Porphyria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/12/10439\">",
"           Clinical manifestations and diagnosis of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/42/5801\">",
"           Congenital erythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40198\">",
"           Etiology and pathogenesis of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3398\">",
"           Management of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/19/28984\">",
"           Porphyrias: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Red cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43880\">",
"           Approach to the child with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/4/18506\">",
"           Bone and joint complications in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/37/36441\">",
"           Causes of congenital and acquired sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6138\">",
"           Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/25/4505\">",
"           Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/50/39719\">",
"           Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/62/13289\">",
"           Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11562\">",
"           Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30775\">",
"           Hematopoietic cell transplantation in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/16/15623\">",
"           Hereditary elliptocytosis: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/56/43911\">",
"           Hereditary elliptocytosis: Genetics and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20506\">",
"           Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/40/8841\">",
"           Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26842\">",
"           Inherited aplastic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/37/16984\">",
"           Introduction to hemoglobin mutations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/58/35750\">",
"           Pathophysiology of the sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/58/27559\">",
"           Pyruvate kinase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5399\">",
"           Related disorders of the hexose monophosphate shunt and glutathione metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42200\">",
"           Stomatocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/15/14583\">",
"           Xerocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sickle cell disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/4/18506\">",
"           Bone and joint complications in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23017\">",
"           Diagnosis and management of priapism in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42856\">",
"           Diagnosis of sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30775\">",
"           Hematopoietic cell transplantation in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/1/39961\">",
"           Management of fever in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42170\">",
"           Overview of the clinical manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39946\">",
"           Overview of the management of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20858\">",
"           Protection against malaria in the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27082\">",
"           Pulmonary complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6202\">",
"           Renal manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/1/38937\">",
"           Routine comprehensive care for children with sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30104\">",
"           Sickle hemoglobin polymer: Structure and functional properties",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/33/34330\">",
"           Specific therapies for sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/26/16810\">",
"           The acute chest syndrome in children and adolescents with sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/5/5209\">",
"           Variant sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14330\">",
"           Vasoocclusion in sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Spleen and lymph nodes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/34/12840\">",
"           Approach to the child with an enlarged spleen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33128\">",
"           Approach to the child with peripheral lymphadenopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30744\">",
"           Causes of peripheral lymphadenopathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Systemic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35704\">",
"           Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6697\">",
"           Extrinsic nonimmune hemolytic anemia due to systemic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3098\">",
"           Hematologic manifestations of HIV infection: Anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44039\">",
"           Hematologic manifestations of HIV infection: Neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14522\">",
"           Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/42/27303\">",
"           Hematologic problems in children and adolescents with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30649\">",
"           Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thalassemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/13/38106\">",
"           Clinical manifestations and diagnosis of the thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/25/5529\">",
"           Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/36/43591\">",
"           Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/11/36025\">",
"           Pathophysiology of alpha thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8058\">",
"           Pathophysiology of beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20858\">",
"           Protection against malaria in the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25880\">",
"           Specific issues related to hematopoietic cell transplantation in beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/39/7802\">",
"           Treatment of beta thalassemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         White cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24745\">",
"           Approach to the patient with eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/12/3274\">",
"           Approach to the patient with lymphocytosis or lymphocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29511\">",
"           Approach to the patient with neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35705\">",
"           Causes of neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/53/21338\">",
"           Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24937\">",
"           Congenital neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42966\">",
"           Cyclic neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31303\">",
"           Definition and mechanisms of leukocytosis and neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17048\">",
"           Determinants of neutrophil movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21850\">",
"           Drug-induced neutropenia and agranulocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/3/20537\">",
"           Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/5/41050\">",
"           Hemophagocytic lymphohistiocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42520\">",
"           Immune neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10473\">",
"           Infectious causes of neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/50/32551\">",
"           Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6650\">",
"           Neutrophil functions other than movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/2/6185\">",
"           Normal neutrophil development and kinetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18170\">",
"           Overview of neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/20/30022\">",
"           Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-8873582DC8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_4_8259=[""].join("\n");
var outline_f8_4_8259=null;
var title_f8_4_8260="CT tuberculous enteritis";
var content_f8_4_8260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Tuberculous enteritis - computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced computed tomography of histologically proven ileocecal tuberculosis showing thickened terminal ileum (black arrow), ileocecal valve (red arrow), and cecum (white arrow) with enlarged necrotic ileocecal lymph nodes (yellow arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sudhakar Venkatesh, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8260=[""].join("\n");
var outline_f8_4_8260=null;
var title_f8_4_8261="Sucralfate: Pediatric drug information";
var content_f8_4_8261=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sucralfate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"    see \"Sucralfate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/47/17140?source=see_link\">",
"    see \"Sucralfate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carafate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sucralfate;",
"     </li>",
"     <li>",
"      Dom-Sucralfate;",
"     </li>",
"     <li>",
"      Novo-Sucralate;",
"     </li>",
"     <li>",
"      Nu-Sucralate;",
"     </li>",
"     <li>",
"      PMS-Sucralate;",
"     </li>",
"     <li>",
"      Sucralfate-1;",
"     </li>",
"     <li>",
"      Sulcrate&reg;;",
"     </li>",
"     <li>",
"      Sulcrate&reg; Suspension Plus;",
"     </li>",
"     <li>",
"      Teva-Sucralfate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"      see \"Sucralfate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Dose not established; doses of 40-80 mg/kg/day divided every 6 hours have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stomatitis: 5-10 mL (1 g/10 mL); swish and spit or swish and swallow 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stress ulcer prophylaxis: 1 g 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stress ulcer treatment: 1 g every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duodenal ulcer:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 1 g 4 times/day for 4-8 weeks, or alternatively 2 g twice daily; treatment is recommended for 4-8 weeks in adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: Prophylaxis: 1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Stomatitis: 1 g/10 mL suspension, swish and spit or swish and swallow 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Proctitis: Rectal enema: 2 g/20 mL once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage comment in renal impairment:",
"     </b>",
"     Aluminum salt is minimally absorbed (&lt;5%), however, may accumulate in renal failure",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 1 g/10 mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carafate&reg;: 1 g/10 mL (420 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carafate&reg;: 1 g [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer on an empty stomach 1 hour before meals and at bedtime; tablet may be broken or dissolved in water before ingestion; do not administer antacids within 30 minutes of administration; shake suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: May administer oral suspension as rectal enema; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term management of duodenal ulcers; gastric ulcers; suspension may be used topically for treatment of stomatitis due to cancer chemotherapy or other causes of esophageal, gastric, and rectal erosions; treatment of NSAID mucosal damage; prevention of stress ulcers",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sucralfate may be confused with salsalate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Carafate&reg; may be confused with Cafergot&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F223571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Back pain, bezoar formation, diarrhea, dizziness, flatulence, headache, gastric discomfort; hypersensitivity (urticaria, angioedema, facial swelling, laryngospasm, respiratory difficulty, rhinitis); indigestion, insomnia, nausea, pruritus, rash, sleepiness, vertigo, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sucralfate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in renal failure due to accumulation of aluminum",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because of the potential for sucralfate to alter the absorption of some drugs, separate administration times (administer other medications 2 hours before or after sucralfate) should be considered when alterations in bioavailability are believed to be critical",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Sucralfate may decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Sucralfate may decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin.  Management: Administer digoxin at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Sucralfate may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products such as sucralfate) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: Sucralfate may decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide.  Management: Avoid concomitant oral administration of furosemide and sucralfate. Separate administration by at least 2 hours. Does not apply to parenterally administered furosemide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Sucralfate may decrease the serum concentration of Levothyroxine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Sucralfate may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Sucralfate may decrease the serum concentration of QuiNIDine. Specifically, sucralfate may decrease the absorption of quinidine.  Management: Administer quinidine at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Sucralfate may decrease the serum concentration of Quinolone Antibiotics.  Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Sucralfate may decrease the absorption of Tetracycline Derivatives.  Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sucralfate may diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists.  Management: Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with absorption of vitamin A, vitamin D, vitamin E, and vitamin K",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F223507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Sucralfate is only minimally absorbed following oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aluminum salt of sulfated sucrose which in the presence of acid pH (gastric acid) forms a complex, paste-like substance that adheres to the damaged mucosal area. This selectively forms a protective coating that protects the lining against peptic acid, pepsin, and bile salts.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     GI protection effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acid neutralizing capacity: 14-17 mEq/1 g dose of sucralfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &lt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 90% excreted in stool; small amounts that are absorbed are excreted in the urine as unchanged compounds",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/47/17140?source=see_link\">",
"      see \"Sucralfate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth; separate times of administration with other medications by at least 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There is approximately 14-16 mEq acid neutralizing capacity per 1 g sucralfate",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral suspension is available (100 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 100 mg/mL oral suspension may be made with tablets. Crush eight 1 g tablets in a mortar and reduce to a fine powder. Add ~20 mL of Sterile Water for Injection and mix to a uniform paste; add an additional 20 mL of Sterile Water for Injection and mix thoroughly making a smooth slurry. Add 40 mL of 70% Sorbitol solution. In a separate container, dissolve two flavor packets (Vari-Flavors; Ross Laboratories) with 10 mL of water, add to mortar, and mix well. Transfer to a calibrated bottle, rinse mortar with Sterile Water for Injection, and add quantity of vehicle sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\". Stable for 14 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Melko GP, Turco TF, Phelan TF, et al, &ldquo;Treatment of Radiation-Induced Proctitis With Sucralfate Enemas,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(12):1274-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8261/abstract-text/10630828/pubmed\" id=\"10630828\" target=\"_blank\">",
"        10630828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12811 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8261=[""].join("\n");
var outline_f8_4_8261=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223520\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223521\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062414\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062409\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223498\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223484\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062417\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062416\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223573\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223571\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062421\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062408\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062407\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300087\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223493\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062424\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223495\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223507\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062406\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062419\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062420\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062413\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062422\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806440\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12811\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12811|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=related_link\">",
"      Sucralfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/47/17140?source=related_link\">",
"      Sucralfate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_4_8262="Zoledronic acid: Patient drug information";
var content_f8_4_8262=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zoledronic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     see \"Zoledronic acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Reclast&reg;;",
"     </li>",
"     <li>",
"      Zometa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aclasta&reg;;",
"     </li>",
"     <li>",
"      Zometa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11442017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used when treating some cancers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Paget's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off or treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703149",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zoledronic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Reclast&reg;: If you have low calcium levels or very bad kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697041",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are dehydrated, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have malabsorption syndrome or have had part of your bowel taken out, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had thyroid or parathyroid surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a dental exam before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698147",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High or low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698211",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone, joint, or muscle pain may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2927622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A broken leg may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the jaw bone may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone, joint, or muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2927623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad groin or thigh pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Twitching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen may be given to lower fever and chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3522422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Recast&reg;: Drink at least 2 glasses of liquids a few hours before you get this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11155 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8262=[""].join("\n");
var outline_f8_4_8262=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235968\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235969\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442017\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025156\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025155\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025160\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025161\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025163\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025158\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025159\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025164\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025165\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=related_link\">",
"      Zoledronic acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_4_8263="Hydrochlorothiazide: Drug information";
var content_f8_4_8263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/20/10565?source=see_link\">",
"    see \"Hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"    see \"Hydrochlorothiazide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Microzide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydro&reg;;",
"     </li>",
"     <li>",
"      Bio-Hydrochlorothiazide;",
"     </li>",
"     <li>",
"      Dom-Hydrochlorothiazide;",
"     </li>",
"     <li>",
"      Novo-Hydrazide;",
"     </li>",
"     <li>",
"      Nu-Hydro;",
"     </li>",
"     <li>",
"      PMS-Hydrochlorothiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Edema (diuresis):",
"     </b>",
"     Oral: 25-100 mg/day in 1-2 doses; maximum: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 12.5-50 mg/day; minimal increase in response and more electrolyte disturbances are seen with doses &gt;50 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F179625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"      see \"Hydrochlorothiazide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension, edema (diuretic):",
"     </b>",
"     Oral (effect of drug may be decreased when used every day):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;6 months: 1-3 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;6 months to 2 years: 1-3 mg/kg/day in 2 divided doses; maximum: 37.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2-17 years: Initial: 1 mg/kg/day; maximum: 3 mg/kg/day (50 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients, chlorothiazide may be preferred over hydrochlorothiazide as there are more dosage formulations (eg, suspension) available.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 12.5-25 mg once daily; minimal increase in response and more electrolyte disturbances are seen with doses &gt;50 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F179606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use. Usually ineffective with GFR &lt;30 mL/minute. Effective at lower GFR in combination with a loop diuretic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2009 Heart Failure guidelines suggest that thiazides lose their efficacy when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with caution and monitor for precipitation of hepatic coma.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Microzide&reg;: 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 12.5 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F179575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food or milk. Take early in day to avoid nocturia. Take the last dose of multiple doses no later than 6 PM unless instructed otherwise.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild-to-moderate hypertension; treatment of edema in heart failure and nephrotic syndrome",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F179642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of lithium-induced diabetes insipidus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HCTZ is an error-prone abbreviation (mistaken as hydrocortisone)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hydrochlorothiazide may be confused with hydrocortisone, Viskazide&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Microzide&trade; may be confused with Maxzide&reg;, Micronase&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Esidrex [multiple international markets] may be confused with Lasix brand name for furosemide [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Esidrix [Germany] may be confused with Lasix brand name for furosemide [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined; with capsule formulation, adverse events were observed at doses &ge;25 mg in adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme, exfoliative dermatitis, photosensitivity, purpura, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia, hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, cramping, diarrhea, epigastric distress, gastric irritation, nausea, pancreatitis, sialadenitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Glycosuria, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm, paresthesia, restlessness, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision (transient), xanthopsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis, renal dysfunction, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory distress, pneumonitis, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reactions, necrotizing angiitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic myocarditis, eosinophilic pneumonitis, hepatic function impairment, hypercalcemia, lip cancer (Friedman, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrochlorothiazide or any component of the formulation, thiazides, or sulfonamide-derived drugs; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid in severe renal disease (ineffective).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F179594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Hydrochlorothiazide peak serum levels may be decreased if taken with food. This product may deplete potassium, sodium, and magnesium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice); may diminish the antihypertensive effect of hydrochlorothiazide. Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse); may enhance the hypotensive effect of hydrochlorothiazide.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B  (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Thiazide diuretics cross the placenta and are found in cord blood. Maternal use may cause may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults. Use of thiazide diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F179610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10923724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thiazide diuretics are found in breast milk. Following a single oral maternal dose of hydrochlorothiazide 50 mg, the mean breast milk concentration was 80 ng/mL (samples collected over 24 hours) and hydrochlorothiazide was not detected in the blood of the breast feeding infant (limit of detection 20 ng/mL). Peak plasma concentrations reported in adults following hydrochlorothiazide 12.5-100 mg are 70-490 ng/mL.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9550527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food or milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F179581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $42.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Microzide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $132.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $82.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $8.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $16.45",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F179569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess weight, I &amp; O reports daily to determine fluid loss; blood pressure, serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F179583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acortiz (MX);",
"     </li>",
"     <li>",
"      Apo-Hydro (MY);",
"     </li>",
"     <li>",
"      BPzide (IN);",
"     </li>",
"     <li>",
"      Chlothia (JP);",
"     </li>",
"     <li>",
"      Di-Ertride (SG);",
"     </li>",
"     <li>",
"      Di-Eudrin (VE);",
"     </li>",
"     <li>",
"      Dichlotride (BE, DK, HK, LU, NL, PT, TH);",
"     </li>",
"     <li>",
"      Dichlozid (KP);",
"     </li>",
"     <li>",
"      Didralin (SG);",
"     </li>",
"     <li>",
"      Disalunil (BG, PL);",
"     </li>",
"     <li>",
"      Disothiazide (IL);",
"     </li>",
"     <li>",
"      Dithiazide (AU);",
"     </li>",
"     <li>",
"      Diurace (PE);",
"     </li>",
"     <li>",
"      Diuret-P (TH);",
"     </li>",
"     <li>",
"      Diurex (AR);",
"     </li>",
"     <li>",
"      Diurix (BR);",
"     </li>",
"     <li>",
"      Diursan (PY);",
"     </li>",
"     <li>",
"      Diuzid (PH);",
"     </li>",
"     <li>",
"      Esidrex (AE, AT, BB, BE, BF, BH, BJ, BM, BS, BZ, CH, CI, CY, EG, ET, FR, GH, GM, GN, GR, GY, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, NO, OM, QA, SA, SC, SD, SE, SL, SN, SR, SY, TN, TT, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Esidrix (DE);",
"     </li>",
"     <li>",
"      H.C.T. (ID);",
"     </li>",
"     <li>",
"      HCT (EC);",
"     </li>",
"     <li>",
"      Hidroronol (CN);",
"     </li>",
"     <li>",
"      Hidrosaluretil (ES);",
"     </li>",
"     <li>",
"      Hychlozide (TH);",
"     </li>",
"     <li>",
"      Hydrex (FI);",
"     </li>",
"     <li>",
"      Hydro-Saluric (GB, IE);",
"     </li>",
"     <li>",
"      Hydrochlorothiazidum (PL);",
"     </li>",
"     <li>",
"      Hydrochlorzide (MY);",
"     </li>",
"     <li>",
"      Hydrozide (HK, TH);",
"     </li>",
"     <li>",
"      Hypothiazid (HN, HU, RU);",
"     </li>",
"     <li>",
"      Hytaz (PH);",
"     </li>",
"     <li>",
"      Lonpra (CO);",
"     </li>",
"     <li>",
"      Maschitt (JP);",
"     </li>",
"     <li>",
"      Newtolide (JP);",
"     </li>",
"     <li>",
"      Pantemon (JP);",
"     </li>",
"     <li>",
"      Ridaq (ZA);",
"     </li>",
"     <li>",
"      Rofucal (MX);",
"     </li>",
"     <li>",
"      Tandiur (AR);",
"     </li>",
"     <li>",
"      Tiazid (PE);",
"     </li>",
"     <li>",
"      Unazid (HR);",
"     </li>",
"     <li>",
"      Urilzid (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F179577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~50% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 3.6-7.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 50% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5.6-14.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Berns JS, Brier ME, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults",
"      </i>",
"      , 4th ed. Philadelphia, PA: American College of Physicians; 1999.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman GD, Asgari MM, Warton EM, et al, \"Antihypertensive Drugs and Lip Cancer in Non-Hispanic Whites,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2012, 6:1-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/22869299/pubmed\" id=\"22869299\" target=\"_blank\">",
"        22869299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller ME, Cohn RD, and Burghart PH, \"Hydrochlorothiazide Disposition in a Mother and Her Breast-Fed Infant,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1982, 101(5):789-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/7131161/pubmed\" id=\"7131161\" target=\"_blank\">",
"        7131161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8263/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8529 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8263=[""].join("\n");
var outline_f8_4_8263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179599\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179646\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179604\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179625\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179605\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179606\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897538\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179571\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179556\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179575\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179574\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179642\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179654\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179644\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179578\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179560\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299455\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179565\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179594\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179567\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179582\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179610\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923724\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9550527\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179581\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179569\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179583\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179559\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179577\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/20/10565?source=related_link\">",
"      Hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=related_link\">",
"      Hydrochlorothiazide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_4_8264="Fluvastatin: Drug information";
var content_f8_4_8264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluvastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/7/36980?source=see_link\">",
"    see \"Fluvastatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/54/11111?source=see_link\">",
"    see \"Fluvastatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16054979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lescol&reg;;",
"     </li>",
"     <li>",
"      Lescol&reg; XL",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lescol&reg;;",
"     </li>",
"     <li>",
"      Lescol&reg; XL;",
"     </li>",
"     <li>",
"      Teva-Fluvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F173548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F173511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Dyslipidemia (also delay in progression of CAD):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Patients requiring &ge;25% decrease in LDL-C:",
"     </i>",
"     40 mg capsule once daily in the evening, 80 mg extended release tablet once daily (anytime), or 40 mg capsule twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Patients requiring &lt;25% decrease in LDL-C:",
"     </i>",
"     Initial: 20 mg capsule once daily in the evening; may increase based on tolerability and response to a maximum recommended dose of 80 mg/day, given in 2 divided doses (immediate release capsule) or as a single daily dose (extended release tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Concomitant use with cyclosporine or fluconazole:",
"     </i>",
"     Do not exceed fluvastatin 20 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2931789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/54/11111?source=see_link\">",
"      see \"Fluvastatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Heterozygous familial hypercholesterolemia:",
"     </b>",
"     Adolescents 10-16 years: Oral: Initial: 20 mg once daily; may increase every 6 weeks based on tolerability and response to a maximum recommended dose of 80 mg/day, given in 2 divided doses (immediate release capsule) or as a single daily dose (extended release tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Indicated only for adjunctive therapy when diet alone cannot reduce LDL-C below 190 mg/dL, or 160 mg/dL (with cardiovascular risk factors). Female patients must be 1 year postmenarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Concomitant use with cyclosporine or fluconazole:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F173512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F173513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Less than 6% excreted renally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate renal impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe renal impairment: Use with caution (particularly at doses &gt;40 mg/day; has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F173514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Manufacturer labeling does not provide specific dosing recommendations; however, systemic exposure may be increased in patients with liver disease  (increased AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     ); use is contraindicated in active liver disease or unexplained transaminase elevations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lescol&reg;: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lescol&reg; XL: 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsules",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F173484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient should be placed on a standard cholesterol-lowering diet before and during treatment. Fluvastatin may be taken without regard to meals. Adjust dosage as needed in response to periodic lipid determinations during the first 4 weeks after a dosage change; lipid-lowering effects are additive when fluvastatin is combined with a bile-acid binding resin or niacin, however, it must be administered at least 2 hours following these drugs. Do not break, chew, or crush extended release tablets; do not open capsules.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F173483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To be used as a component of multiple risk factor intervention in patients at risk for atherosclerosis vascular disease due to hypercholesterolemia",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Adjunct to dietary therapy to reduce elevated total cholesterol (total-C), LDL-C, triglyceride, and apolipoprotein B (apo-B) levels and to increase HDL-C in primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb); to slow the progression of coronary atherosclerosis in patients with coronary heart disease; reduce risk of coronary revascularization procedures in patients with coronary heart disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluvastatin may be confused with fluoxetine, nystatin, pitavastatin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F173546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported with fluvastatin capsules; in general, adverse reactions reported with fluvastatin extended release tablet were similar, but the incidence was less.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9%), fatigue (3%), insomnia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (8%), diarrhea (5%), abdominal pain (5%), nausea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (3%), bronchitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening) including additional class-related events (not necessarily reported with fluvastatin therapy): Alopecia, amnesia (reversible), anaphylaxis, angioedema, arthralgia, arthritis, blood glucose increased, cataracts, cholestatic jaundice, cirrhosis, cognitive impairment (reversible), confusion (reversible), CPK increased (&gt;10x normal), depression, dermatomyositis, dyspnea, eosinophilia, erectile dysfunction, erythema multiforme, ESR increased, facial paresis, fatty liver, fever, fulminant hepatic necrosis, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, gynecomastia, hemolytic anemia, hepatitis, hepatoma, hypersensitivity reaction, immune-mediated necrotizing myopathy (IMNM), impotence, interstitial lung disease, leukopenia, memory disturbance (reversible), memory impairment (reversible), muscle cramps, myopathy, nodules, ophthalmoplegia, pancreatitis, paresthesia, peripheral nerve palsy, peripheral neuropathy, photosensitivity, polymyalgia rheumatica, positive ANA, pruritus, psychic disturbance, purpura, rash, renal failure (secondary to rhabdomyolysis), rhabdomyolysis, skin discoloration, Stevens-Johnson syndrome, systemic lupus erythematosus-like syndrome, taste alteration, thrombocytopenia, thyroid dysfunction, toxic epidermal necrolysis, transaminases increased, tremor, urticaria, vasculitis, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F173487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluvastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F173469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart fluvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose related and is increased with concurrent use of cyclosporine, erythromycin, or other lipid-lowering medications (eg, fibrates, niacin at doses &ge;1 g/day). The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases reducing steroidogenesis: Use caution in patients with conditions or on medications that reduce steroidogenesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated in patients with active liver disease or unexplained transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age; these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F173542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor), SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C8 (weak), CYP2C9 (moderate), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Fluvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the serum concentration of Fluvastatin. Management: Administer fluvastatin at least 1 hour or greater (particularly with extended-release form) before, or at least 4 hours after cholestyramine to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Fluvastatin. Management: Limit fluvastatin to 20 mg/day in patients who are also receiving cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Fluvastatin. Management: Limit fluvastatin maximum  adult dose to 20 mg/day, and monitor for toxic effects of fluvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities), during concomitant treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Fluvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Fluvastatin. Management: Use fluvastatin at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Fluvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F173501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid excessive ethanol consumption (due to potential hepatic effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Reduces rate but not the extent of absorption. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F173490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F173518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F173491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluvastatin is excreted in human breast milk (milk plasma ratio 2:1); do not use in breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F173492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Generally, patients should be placed on a standard cholesterol-lowering diet and other lifestyle modifications for 3-6 months prior to the initiation of drug therapy. The diet should be continued during drug therapy. However, for patients with advanced risk factors (eg, known coronary heart disease), drug therapy may be initiated concurrently with diet modification. May be taken without regard to meals. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F173489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Fluvastatin Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $113.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $113.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lescol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $152.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $152.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Lescol XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $194.69",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F173478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Upon initiation or titration, lipid panel should be analyzed at 4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F173493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cranoc (DE);",
"     </li>",
"     <li>",
"      Digaril (ES);",
"     </li>",
"     <li>",
"      Fractal (FR);",
"     </li>",
"     <li>",
"      Fractal LP (FR);",
"     </li>",
"     <li>",
"      Lescol (AE, AR, AT, AU, BB, BE, BH, BM, BR, BS, BZ, CH, CL, CO, CY, CZ, DK, EE, EG, FI, FR, GB, GR, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JM, JO, KP, KW, LB, LY, MX, MY, NL, NO, NZ, OM, PE, PH, PL, PT, QA, RU, SA, SE, SG, SR, SY, TH, TR, TT, TW, VE, YE);",
"     </li>",
"     <li>",
"      Lescol LP (FR);",
"     </li>",
"     <li>",
"      Lescol XL (AU, BG, EC, GB, ID, KP, MX, MY, PE, PH, SG, TH, TW);",
"     </li>",
"     <li>",
"      Leucol (CN);",
"     </li>",
"     <li>",
"      Lochol (JP);",
"     </li>",
"     <li>",
"      Locol (DE);",
"     </li>",
"     <li>",
"      Lymetel (ES);",
"     </li>",
"     <li>",
"      Vastin (AU);",
"     </li>",
"     <li>",
"      Xilep (KP);",
"     </li>",
"     <li>",
"      Xilep XL (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F173468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts by competitively inhibiting 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the reduction of HMG-CoA to mevalonate; this is an early rate-limiting step in cholesterol biosynthesis. HDL is increased while total, LDL, and VLDL cholesterols; apolipoprotein B; and plasma triglycerides are decreased.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F173486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Maximal LDL-C reductions achieved within 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.35 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To inactive and active metabolites (oxidative metabolism via CYP2C9 [75%], 2C8 [~5%], and 3A4 [~20%] isoenzymes); active forms do not circulate systemically; extensive (saturable) first-pass hepatic extraction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: Capsule: 24%; Extended release tablet: 29%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Capsule: &lt;3 hours; Extended release tablet: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Capsule: 1 hour; Extended release tablet: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (90%): urine (5%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134(4):824-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/18689579/pubmed\" id=\"18689579\" target=\"_blank\">",
"        18689579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 103(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/11136683/pubmed\" id=\"11136683\" target=\"_blank\">",
"        11136683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren MJ, Smith DG, Hunninghake DB, et al, &ldquo;The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients. A Comparison of Atorvastatin, Simvastatin, Lovastatin, and Fluvastatin,&rdquo;",
"      <i>",
"       Pharmacoeconomics",
"      </i>",
"      , 1998, 14(1):59-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/10182195/pubmed\" id=\"10182195\" target=\"_blank\">",
"        10182195",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9326):7-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/12114036/pubmed\" id=\"12114036\" target=\"_blank\">",
"        12114036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(3):499-511.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/12551878/pubmed\" id=\"12551878\" target=\"_blank\">",
"        12551878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips BG, Yim JM, Brown EJ Jr, et al, &ldquo;Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1996, 131(5):872-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/8615304/pubmed\" id=\"8615304\" target=\"_blank\">",
"        8615304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(20):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/7566020/pubmed\" id=\"7566020\" target=\"_blank\">",
"        7566020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/4/8264/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8473 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8264=[""].join("\n");
var outline_f8_4_8264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16054979\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173506\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173507\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173548\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173511\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2931789\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173512\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173513\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173514\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173480\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173465\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173484\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173483\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173556\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173546\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173487\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173469\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173542\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173474\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173501\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173476\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173490\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173518\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173491\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173492\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173489\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173478\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173493\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173468\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173486\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8473\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8473|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/7/36980?source=related_link\">",
"      Fluvastatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/54/11111?source=related_link\">",
"      Fluvastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_4_8265="Pure red cell aplasia due to anti-erythropoietin antibodies";
var content_f8_4_8265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pure red cell aplasia due to anti-erythropoietin antibodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8265/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8265/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8265/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8265/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8265/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/4/8265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired pure red cell aplasia (PRCA) is a rare condition of profound anemia characterized by a very low reticulocyte count and the virtual absence of erythroid precursors in the bone marrow. All other cell lines are present and seem quantitatively and morphologically normal. Many cases of acquired PRCA are idiopathic. In others, underlying conditions such as thymoma, myelodysplastic syndromes, lymphoma, leukemia, systemic autoimmune disorders, viral infection (ie, parvovirus B19), or treatment with drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    are identified [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link\">",
"     \"Acquired pure red cell aplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PRCA has also been described in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (EPO), resulting from the induction of antibodies directed against the EPO molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/2\">",
"     2",
"    </a>",
"    ]. Most reported cases are in patients with chronic kidney disease (CKD).",
"   </p>",
"   <p>",
"    Pure red cell aplasia due to anti-EPO antibodies in patients with chronic renal failure will be reviewed here. A discussion of other causes of acquired PRCA is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link\">",
"     \"Acquired pure red cell aplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of non-EPO related PRCA are mediated by IgG autoantibodies or cytotoxic T lymphocytes directed against erythroid precursor or progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Inhibition of erythropoiesis occurs primarily between the Colony Forming Unit&ndash;erythroid (CFU-E) and proerythroblast stages. The proerythroblast is the first morphologically identifiable erythroid precursor in normal marrow and is virtually absent in the marrow of patients with PRCA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link\">",
"     \"Acquired pure red cell aplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PRCA due to autoantibodies against endogenous erythropoietin is rare in patients who have never been treated with erythropoiesis-stimulating agents (ESAs) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The serum of patients with EPO-related PRCA inhibits the growth of erythroid progenitor cells in bone marrow cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/2\">",
"     2",
"    </a>",
"    ]. Neutralizing IgG antibodies to the protein component of exogenous recombinant EPO are found that cross-react with endogenous erythropoietin.",
"   </p>",
"   <p>",
"    There are several preparations of EPO (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     epoetin alfa",
"    </a>",
"    , epoetin beta, epoetin omega) produced by various manufacturers around the world. These differ from each other and from the native hormone in terms of glycosylation and sialic acid content [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/7\">",
"     7",
"    </a>",
"    ]. The vast majority of cases of EPO-related PRCA have occurred in patients treated with a particular epoetin alfa product: Eprex (in single use syringes), which is manufactured and distributed outside the United States. Altered antigenicity of this specific product has been suggested as the underlying cause of anti-EPO antibody development. Although the precise mechanisms remain under investigation, possible explanations thus far include use of polysorbate as a stabilizing agent and the presence of organic compounds in the implicated preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human serum albumin (HSA) is used as a stabilizing agent in many EPO preparations, although polysorbate is used in some to preclude the hypothetical risk of transmitting infectious agents via the HSA. Two products are stabilized with polysorbates, Eprex with polysorbate 80, and NeoRecormon (epoetin beta) with polysorbate 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8\">",
"     8",
"    </a>",
"    ]. Eprex is much more often implicated in PRCA, thus the enhanced immunogenicity may be related to the type of polysorbate. Particularly under conditions of inappropriate storage and handling, such as high temperatures, EPO molecules may aggregate and elicit an antibody response [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports suggest that the cause for the increased incidence of PRCA with Eprex was organic compounds leached by polysorbate from uncoated rubber stoppers in prefilled syringes. These organic compounds were not found in Eprex preparations provided in syringes with coated rubber stoppers, in vials with polysorbate, or in preparations with HSA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. These compounds may act as adjuvants to increase the immunogenicity of Eprex. The rate of PRCA was significantly higher after exposure to Eprex in uncoated rubber stopper syringes compared to coated rubber stopper syringes, or in Eprex preparations stabilized with HSA. Despite this, the role of leachates has been disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually all reported cases of anti-EPO antibody mediated PRCA have occurred in patients with chronic kidney disease (CKD) who have received the drug subcutaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/2,8,9,15\">",
"     2,8,9,15",
"    </a>",
"    ]. Although not specifically studied with EPO, subcutaneous administration of other drugs has been associated with greater immunogenicity than with intravenous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These considerations prompted the manufacturer to replace uncoated rubber stoppers with fluoro-resin coated stoppers and to change the prescribing information of Eprex with polysorbate to intravenous route for patients with chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As a result, the incidence of PRCA has rapidly fallen to its previous baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of EPO-related PRCA have occurred in patients with renal failure in Europe and the United Kingdom, but patients in Canada, Australia, and countries in Asia have also been affected [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,19\">",
"     8,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The condition remains extremely rare given the widespread use of EPO [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The overall incidence of reported cases between 1989 and June 2004 was 1.6 per 10,000 patient-years of subcutaneous exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/10\">",
"     10",
"    </a>",
"    ]. There have been only two cases reported in patients treated with intravenously administered EPO, with an incidence of 0.02 per 10,000 patient-years of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Eprex",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been over 200 reported cases of PRCA related to Eprex use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/23\">",
"     23",
"    </a>",
"    ], representing the vast majority of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. There was a substantial increase in the number of reported cases between 2001 and 2003, almost exclusively in patients with chronic kidney disease who received Eprex subcutaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,10,19\">",
"     8,10,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This increase in the number of cases was later discovered to coincide with the release of a new formulation and packaging of EPO, as discussed above. The incidence was 3.43 per 10,000 patient-years of exposure for Eprex supplied in syringes with uncoated rubber stoppers compared to 0.23 and 0.17 per 10,000 patient-years for Eprex preparations in coated rubber stopper syringes and stabilized with HSA, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Non-Eprex cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of reported cases between 1989 and 2004 of PRCA with subcutaneous use of non-Eprex preparations was much lower, ranging from 0.02 to 0.16 per 10,000 patient-years between 1989 and 2004, depending on the preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,19,22,24,25\">",
"     8,19,22,24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eleven cases have been attributed to the administration of NeoRecormon, which is an epoetin beta manufactured by Roche and distributed in Europe.",
"     </li>",
"     <li>",
"      Fewer than 10 cases have been described among patients exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       epoetin alfa",
"      </a>",
"      manufactured by Amgen in the US and marketed in the US as either Epogen (Amgen) for treatment of dialysis patients or Procrit (Ortho Biotech) for treatment of anemia in patients not on dialysis.",
"     </li>",
"     <li>",
"      There are now at least two published cases of antibody-mediated pure red cell aplasia in patients exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      (Aranasp) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/23,26-28\">",
"       23,26-28",
"      </a>",
"      ]. Darbepoetin alfa is an erythropoietic stimulating protein with a slightly different amino acid structure and higher sialic acid content than EPO [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link&amp;anchor=H7#H7\">",
"       \"Darbepoetin alfa for the management of anemia in chronic kidney disease\", section on 'Safety and side effect profile'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fortunately, it appears that the incidence of anti-EPO antibody mediated PRCA in patients with kidney disease has declined following changes in storage and handling recommendations and discontinuation of the subcutaneous administration of Eprex [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,19,23,31,32\">",
"     8,19,23,31,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology and pathogenesis'",
"    </a>",
"    above.):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review published in late 2004, the exposure-adjusted incidence decreased worldwide by over 80 percent after the incorporation of such interventions [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was an exposure-related incidence of anti-EPO antibody mediated PRCA of only 0.02 to 0.03 per 10,000 patient-years as reported among EPO manufacturers in December 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    EPO-antibody mediated PRCA has only rarely been reported in children with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/19,34\">",
"     19,34",
"    </a>",
"    ]. In addition, there appears to be a male preponderance in cases related to Eprex (70 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &ldquo;Biosimilar&rdquo; epoetin products are becoming increasingly available around the world; treatment with these agents have also been associated with development of anti-EPO neutralizing antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SCREENING FOR ANTI-EPO ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among dialysis patients, screening for the presence of anti-EPO antibodies cannot be justified. This was shown in a study involving five centers in Canada in which approximately 1500 hemodialysis, peritoneal dialysis, and predialysis patients were screened [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/37\">",
"     37",
"    </a>",
"    ]. Using a radioimmunoprecipitation assay, a low-positive test was noted in only one patient (who had previously been diagnosed with PRCA) and borderline positive assays were observed in only three individuals, none of whom had signs of PRCA. None of the four had neutralizing anti-EPO antibodies.",
"   </p>",
"   <p>",
"    Similar results were obtained in 536 patients screened in 35 German dialysis units [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/38\">",
"     38",
"    </a>",
"    ]. In this study, anti-EPO antibodies were detected in three EPO-hyporesponsive and three EPO-normoresponsive patients using an ELISA assay with only one borderline result with a radioimmunoprecipitation assay. There were no cases of PRCA.",
"   </p>",
"   <p>",
"    However, we agree with the 2012 KDIGO guidelines, which suggest that an evaluation for PRCA due to anti-EPO antibodies should occur in the patient exposed to at least eight weeks of erythropoiesis stimulating agents (ESA) therapy who develops all of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decline in hemoglobin level of more than 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      per week, or transfusion requirement of at least one to two units per week to maintain adequate hemoglobin",
"     </li>",
"     <li>",
"      Normal platelet and white blood cell count",
"     </li>",
"     <li>",
"      Absolute reticulocyte count of less than",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PRCA due to anti-EPO antibodies should be suspected if the hemoglobin level declines by more than 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    per month, or the reticulocyte count is less than",
"    <span class=\"nowrap\">",
"     20,000/microL,",
"    </span>",
"    in an individual who has previously responded to EPO. PRCA generally does not occur unless the patient has been on EPO for at least three to four weeks, and typically occurs after 6 to 18 months' exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PRCA is specifically characterized by the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,40\">",
"     8,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decline in hemoglobin level of more than 0.7 to 1.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      per week without transfusions, or transfusion requirement of at least one unit per week to maintain adequate hemoglobin, despite continued use of EPO at the same or increased doses",
"     </li>",
"     <li>",
"      Markedly reduced reticulocyte count",
"      <span class=\"nowrap\">",
"       (&lt;10,000/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Drop in platelet counts, although generally not below the lower limit of normal",
"     </li>",
"     <li>",
"      Normal white blood cell count",
"     </li>",
"     <li>",
"      Elevated serum transferrin saturation and serum ferritin, reflecting decreased utilization of iron secondary to diminished erythropoiesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allergic urticarial skin reactions at sites of earlier subcutaneous EPO injections have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To properly diagnose the disorder, a bone marrow aspirate and evaluation for the presence of anti-EPO antibodies must be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bone marrow aspirate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow aspirate reveals severe erythroid hypoplasia, with less than five percent red blood cell precursors; evidence of a block in the maturation of erythroid precursors may be present. Platelet and white cell precursors are entirely normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anti-EPO antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of antibodies to EPO is a critical component of the diagnosis. There are several available tests to detect antibodies that bind EPO, each with its own advantages and disadvantages [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radioimmunoprecipitation assay (RIPA) appears to be the most accurate test for detecting anti-erythropoietin antibodies. However, it is not standardized; low affinity antibodies may not be detected; it requires radiolabeled antigen; and it is time consuming and difficult to automate [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enzyme linked immunosorbent assays (ELISA) are more widely available, but appear to have lower sensitivity and specificity than the RIPA [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,43\">",
"       8,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A biosensor assay, which is not as readily available as the previous two assays, may provide better characterization of detected antibodies (ie, binding affinity and isotype). However, it may detect very low-affinity antibodies in baseline sera that never cause PRCA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, these assays can detect antibodies with a concentration of at least 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/42\">",
"     42",
"    </a>",
"    ]. The neutralizing capability of the anti-EPO antibodies cannot be assessed with any of the above-mentioned assays. This requires a bioassay in which patient serum or immunoglobulin inhibits red blood cell precursor growth in bone marrow or cell line cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8,40\">",
"     8,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult to recommend use of any one of these assays over another, given that they are not standardized, they have advantages and disadvantages that are difficult to compare, and are not available commercially [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sample in a suspected case must currently be sent to the manufacturer, where several different assays, including one for neutralizing capability, are performed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/45\">",
"     45",
"    </a>",
"    ]. Confirmation of a suspected case of anti-EPO antibody mediated PRCA should show the presence of anti-erythropoietin antibodies and evidence of neutralizing ability [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/19,40\">",
"     19,40",
"    </a>",
"    ]. Bioassays generally detect antibodies with a concentration of at least 1",
"    <span class=\"nowrap\">",
"     microg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to PRCA due to anti-EPO antibodies, there are a large number of other causes of anemia and hyporesponsiveness to EPO among patients with CKD. They can be distinguished from PRCA largely because the observation that PRCA due to anti-EPO antibodies is associated with a profound fall in hemoglobin level and reticulocyte count [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/42\">",
"     42",
"    </a>",
"    ]. By comparison, the other causes of EPO resistance are associated with less severe drops in counts. Other causes of EPO resistance are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link&amp;anchor=H18#H18\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Hyporesponsiveness to ESAs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with managing PRCA. Treatment consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial management including transfusions for symptomatic anemia and discontinuing all recombinant EPO products.",
"     </li>",
"     <li>",
"      Immunosuppressive therapy to eradicate antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients who do not respond to immunosuppressive therapies and are eligible candidates, consideration should be given to kidney transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most important initial steps in management in anti-EPO antibody mediated PRCA are transfusions for symptomatic anemia and stopping all recombinant EPO products [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/8\">",
"     8",
"    </a>",
"    ]. There are at least three observations underlying the recommendation to avoid",
"    <strong>",
"     any",
"    </strong>",
"    recombinant EPO preparation, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    , in patients with anti-EPO antibody mediated PRCA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-EPO antibodies crossreact not only with the endogenous hormone, but also with all recombinant EPO molecules, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rechallenge with EPO preparations may cause an anamnestic antibody response, making it less possible for the antibody to either spontaneously disappear or return to clinically unimportant levels.",
"     </li>",
"     <li>",
"      Rechallenge with EPO may incite the formation of allergic skin and systemic reactions (eg, anaphylaxis), which might further complicate the patient's clinical picture [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there have been case reports of patients who have tolerated rechallenge [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Despite these case reports, and other isolated instances in which patients appeared to tolerate resumption of EPO therapy or treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/46,50\">",
"     46,50",
"    </a>",
"    ], patients with EPO-associated PRCA should have EPO treatment discontinued and should not routinely be switched to an alternative EPO product or to darbepoetin alfa.",
"   </p>",
"   <p>",
"    If, however, rechallenge is considered for clinical reasons or at the patient request, the following recommendations proposed by a group of European investigators appear reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consider rechallenge only if anti-EPO antibody levels are below or near the lower limit of detection.",
"     </li>",
"     <li>",
"      Closely monitor the absolute reticulocyte count and anti-EPO antibody levels, and for systemic reactions.",
"     </li>",
"     <li>",
"      Administer EPO intravenously whenever feasible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since PRCA in this setting is immune mediated, the condition should respond to immunosuppressive therapy, and while spontaneous remissions after cessation of EPO therapy occur, they appear to be rare; immunosuppressive therapy should probably be provided in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no controlled data, but several different immunosuppressive regimens have been used. In one retrospective review of 47 cases in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/51\">",
"     51",
"    </a>",
"    ], EPO therapy was stopped in all patients. Ten patients did not receive immunosuppressive therapy; one died within six weeks of diagnosis; and nine did not recover by a median follow-up of twelve months.",
"   </p>",
"   <p>",
"    The remaining 37 patients were treated with a variety of immunosuppressive agents. The majority received steroids, alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , intravenous gamma globulin (IVIG), or plasmapheresis, six received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    alone, one received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and two received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Six patients received a kidney transplant. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seventy-eight percent of all patients recovered, most within three months.",
"     </li>",
"     <li>",
"      Recovery occurred only after antibody levels became undetectable.",
"     </li>",
"     <li>",
"      No relapse of PRCA occurred following cessation of immunosuppression, but none of the patients were rechallenged with EPO or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      following recovery.",
"     </li>",
"     <li>",
"      All six patients who received a kidney transplant recovered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Favorable responses were seen with many of the regimens. This included corticosteroids with or without IVIG (10 of 18 recovered), corticosteroids with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (seven of eight recovered) as well as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    alone (four of six recovered), which resulted in the fastest response [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In this study, none of the patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , an antibody against B-cells which has been effective for non-EPO related PRCA, recovered [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/51\">",
"     51",
"    </a>",
"    ], although response to rituximab has been reported elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/53\">",
"     53",
"    </a>",
"    ]. Only one of nine patients who were treated with IVIG alone recovered.",
"   </p>",
"   <p>",
"    In one review, there was an analysis of EPO-related PRCA as reported to the FDA and the manufacturers of several EPO preparations as well as longer term follow up of patients previously reported and described above from the European PRCA Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/51\">",
"     51",
"    </a>",
"    ]. It was concluded that the highest recovery rates were associated with combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and that the highest rates of EPO-responsiveness on rechallenge were in those patients whose anti-EPO antibody levels were undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment recommendations that follow are made with the caveat that worldwide experience is very limited, and none of the data are from randomized controlled trials. Given that the highest recovery rates appear to be associated with combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , we prefer initial therapy consisting of prednisone (1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) plus oral cyclophosphamide (50 to 100 mg per day) for a maximum of three to four months. A reasonable alternative is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    alone at a dose of 200 mg daily (or 100 mg twice daily) for a maximum of three to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/49,54\">",
"     49,54",
"    </a>",
"    ]. Patients who do not respond to treatment with either oral cyclophosphamide plus prednisone or with cyclosporine alone may be treated with the other regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cost, potential toxicities, and limited effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/51\">",
"     51",
"    </a>",
"    ] of intravenous immune globulin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    suggest that these treatments should perhaps be limited to those who fail to respond to other therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of immunosuppressive therapy and monitoring for anti-EPO antibody mediated PRCA is unknown. However, the following recommendations appear reasonable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continue treatment until antibody levels become undetectable or there is no response within three to four months of treatment initiation.",
"     </li>",
"     <li>",
"      Monitor hemoglobin weekly to assess for transfusion requirement and response to therapy.",
"     </li>",
"     <li>",
"      Monitor reticulocyte count and anti-EPO antibody levels every one to two weeks during treatment to assess response or lack thereof.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the majority of patients who respond to treatment do so within three to four months, immunosuppressive therapy should probably be discontinued if there is no response within this time. However, in the above-mentioned study of 37 treated patients, four patients responded five to eighteen months after treatment was initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the introduction of \"biosimilar\" epoetins and increasing use of unlicensed epoetin products in certain parts of the word, ongoing vigilance must be maintained for new occurrences of anti-EPO antibody mediated PRCA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Peginesatide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     Peginesatide",
"    </a>",
"    , formerly called hematide, is a small synthetic peptide that ligands and activates the EPO receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/56\">",
"     56",
"    </a>",
"    ]. Peginesatide stimulates erythroid colony growth, reticulocyte count and hematocrit in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/57\">",
"     57",
"    </a>",
"    ], but, because its amino acid sequence is unrelated to erythropoietin, does not cross react with erythropoietin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     Peginesatide",
"    </a>",
"    may correct anemia in patients with PRCA due to anti-erythropoietin antibodies. An open label study of 14 patients with PRCA due to anti-erythropoietin antibodies reported that the hemoglobin level significantly increased (9 to 11.4",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    after the subcutaneous administration of peginesatide (0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four weeks) for a median period of 28 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Food and Drug Administration approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    for intravenous or subcutaneous administration to treat anemia in adult dialysis patients with CKD but not in CKD patients who are not on dialysis or in patients with cancer-related anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/60\">",
"     60",
"    </a>",
"    ]. However, subsequent to FDA approval, peginesatide was withdrawn from the market due to serious hypersensitivity reactions reported in approximately 0.2 percent of patients following the first dose of intravenous administration with death occurring in 0.02 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/61\">",
"     61",
"    </a>",
"    ]. It is no longer available for use.",
"   </p>",
"   <p>",
"    FDA approval for dialysis patients was based upon two randomized trials (EMERALD 1 and EMERALD 2) in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    administered monthly was as effective as erythropoietin in maintaining hemoglobin concentrations of 10 to 12",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    among dialysis patients who were previously treated and stabilized on erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Peginesatide was equivalent to erythropoietin in regard to cardiovascular safety. Side effects observed in greater than 10 percent of patients included diarrhea, vomiting, hypertension and arthralgias. Long term follow-up is not available. The EMERALD trials are discussed in depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link&amp;anchor=H1130568215#H1130568215\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns had also been raised about the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    among nondialysis CKD patients, and the FDA had not approved the use of peginesatide among such patients. In two randomized trials in nondialysis CKD patients (PEARL 1 and PEARL 2), peginesatide was associated with a higher incidence of a composite cardiovascular safety endpoint compared with darbepoetin (21.5 versus 17.1 percent), although the agents were similarly effective in regard to maintaining target hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8265/abstract/64\">",
"     64",
"    </a>",
"    ]. The reasons for the increased cardiovascular risk with peginesatide are unknown and the increased risk was not observed in the Emerald studies, performed in dialysis patients. The PEARL studies are discussed in depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link&amp;anchor=H16#H16\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of cases of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      (EPO)-related acquired pure red cell aplasia (PRCA) have occurred in patients treated with a particular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       epoetin alfa",
"      </a>",
"      product: Eprex (in single use syringes). The underlying cause may be organic compounds (leached by polysorbate from uncoated rubber stoppers in prefilled syringes) that are acting as adjuvants, resulting in anti-EPO antibody development. Virtually all reported cases of anti-EPO antibody mediated PRCA have occurred in patients with chronic renal failure who have received the drug subcutaneously. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EPO-related PRCA remains extremely rare given the widespread use of EPO. There have been over 200 reported cases of PRCA related to Eprex use, which represents the vast majority of affected patients. Following changes in storage and handling recommendations and discontinuation of subcutaneous administration of Eprex, the incidence of anti-EPO antibody mediated PRCA in patients with kidney disease has declined. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for the presence of anti-EPO antibodies should not be performed in dialysis patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Screening for anti-EPO antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EPO-induced PRCA should be considered in the patient with significant anemia who has been treated with EPO for at least three to four weeks, and has previously responded to treatment with EPO. The condition is characterized by a sudden decline in hemoglobin level despite continued use of EPO, markedly reduced reticulocyte count, and normal white blood cell (WBC) and platelet counts. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To definitively diagnose EPO-induced PRCA, a bone marrow aspirate and evaluation for the presence of neutralizing anti-EPO antibodies should be performed. The bone marrow reveals severe erythroid hypoplasia, with less than five percent red blood cell precursors, and there may be evidence of a block in the maturation of erythroid precursors. Platelet and white cell precursors are entirely normal. Anti-EPO antibodies are detected by radioimmunoprecipitation assay (RIPA), enzyme linked immunosorbent assays (ELISA), or other assay, as available. The sample must be sent to the manufacturer for testing to document the presence of anti-erythropoietin antibodies and evidence of their neutralizing ability. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the cessation of all recombinant EPO preparations in patients with PRCA (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also recommend NOT switching to an alternative EPO product or to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Patients should be transfused for severe symptomatic anemia. Our recommendations concerning rechallenge are discussed below. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given that spontaneous remissions after cessation of EPO therapy are rare, we recommend the administration of immunosuppressive therapy in most patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest initial therapy consisting of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) plus oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (50 to 100 mg per day) for a maximum of three to four months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A reasonable alternative for first-line therapy is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      alone at a dose of 200 mg daily (or 100 mg twice daily) for a maximum of three to four months. Patients who do not respond to initial treatment with either oral cyclophosphamide plus prednisone or with cyclosporine alone may be subsequently treated with the other regimen. Consideration should be given to kidney transplantation in all eligible patients if there is no response to this strategy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"       Peginesatide",
"      </a>",
"      has been associated with serious side effects and has been withdrawn from the market. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Peginesatide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of immunosuppressive therapy and monitoring for anti-EPO antibody mediated PRCA is unknown. However, the following recommendations appear reasonable (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Continue treatment until antibody levels become undetectable or there is no response within three to four months of treatment initiation.",
"     </li>",
"     <li>",
"      Monitor hemoglobin weekly to assess for transfusion requirement and response to therapy.",
"     </li>",
"     <li>",
"      Monitor absolute reticulocyte count and anti-EPO antibody levels every one to two weeks during treatment to assess response or lack thereof.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rechallenge may be considered in patients in whom anti-EPO antibody levels are below or closer to the lower limit of detection. If performed, we recommend administration of EPO intravenously in hemodialysis patients. The Hgb, reticulocyte count, and anti-EPO antibody levels should be closely monitored. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/1\">",
"      Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol 2000; 111:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/2\">",
"      Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/3\">",
"      Krantz S. Anemia due to bone marrow failure: diagnosis and treatment. Compr Ther 1980; 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/4\">",
"      Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975; 30:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/5\">",
"      Bunn HF. Drug-induced autoimmune red-cell aplasia. N Engl J Med 2002; 346:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/6\">",
"      Casadevall N, Dupuy E, Molho-Sabatier P, et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/7\">",
"      Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/8\">",
"      Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/9\">",
"      Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003; 18:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/10\">",
"      Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/11\">",
"      Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity? Pharm Res 2003; 20:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/12\">",
"      Boven K, Knight J, Bader F, et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005; 20 Suppl 3:iii33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/13\">",
"      Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol 2006; 24:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/14\">",
"      Sharma B, Ryan MH, Boven K. Reactions to Eprex's adverse reactions. Nat Biotechnol 2006; 24:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/15\">",
"      Quint L, Casadevall N, Giraudier S. Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br J Haematol 2004; 124:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/16\">",
"      Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/17\">",
"      Sibbald B. Eprex warning issued, but no ban. CMAJ 2004; 170:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/18\">",
"      Cournoyer D, Toffelmire EB, Wells GA, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/19\">",
"      Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/20\">",
"      Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997; 47:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/21\">",
"      Peces R, de la Torre M, Alc&aacute;zar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996; 335:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/22\">",
"      Gershon SK, Luksenburg H, Cot&eacute; TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/23\">",
"      Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005; 20 Suppl 4:iv9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/24\">",
"      Macdougall IC. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opin 2004; 20:83.",
"     </a>",
"    </li>",
"    <li>",
"     Amgen Statement on Pure Red Cell Aplasia. www.amgen.com/clinicians/prca.html (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     www.hc-sc.gc.ca, search term Aranasp, accessed December, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/27\">",
"      Jacob A, Sandhu K, Nicholas J, et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant 2006; 21:2963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/28\">",
"      Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant 2007; 22:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/29\">",
"      Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 Suppl 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/30\">",
"      Macdougall IC. Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int Suppl 2002; :55.",
"     </a>",
"    </li>",
"    <li>",
"     www.jnjpharmarnd.com/company/n-casereports.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/32\">",
"      Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia \"epidemic\"--mystery completely revealed? Perit Dial Int 2007; 27 Suppl 2:S303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/33\">",
"      McKoy, JM, et al. Transfusion 2008; 48:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/34\">",
"      Alonso Melgar A, Melgosa Hijosa M, Pardo de la Vega R, et al. Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution. Pediatr Nephrol 2004; 19:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/35\">",
"      Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/36\">",
"      Haag-Weber M, Eckardt KU, H&ouml;rl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-&alpha; (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012; 77:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/37\">",
"      Wu G, Wadgymar A, Wong G, et al. A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers. Am J Kidney Dis 2004; 44:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/38\">",
"      Stoffel MP, Haverkamp H, Kromminga A, et al. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia. Nephron Clin Pract 2007; 105:c90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/39\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/40\">",
"      Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 2004; 73:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/41\">",
"      Weber G, Gross J, Kromminga A, et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002; 13:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/42\">",
"      Pollock C, Johnson DW, H&ouml;rl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/43\">",
"      Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004; 96:c88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/44\">",
"      Thorpe R, Swanson SJ. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 2005; 20 Suppl 4:iv16.",
"     </a>",
"    </li>",
"    <li>",
"     Amgen, Inc., Medical Information. Direct communication, June 16, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/46\">",
"      Asari A, Gokal R. Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis. J Am Soc Nephrol 2004; 15:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/47\">",
"      Summers SA, Matijevic A, Almond MK. Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. Nephrol Dial Transplant 2004; 19:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/48\">",
"      Macdougall IC, Roche A, Rossert J, et al. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? Nephrol Dial Transplant 2004; 19:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/49\">",
"      Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant 2005; 20 Suppl 4:iv23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/50\">",
"      Viron B, Dupuy CA, Kolta A, Casadevall N. Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs. Nephrol Dial Transplant 2008; 23:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/51\">",
"      Verhelst D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004; 363:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/52\">",
"      Chng WJ, Tan LK, Liu TC. Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am J Kidney Dis 2003; 41:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/53\">",
"      Mandreoli M, Finelli C, Lopez A, et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis 2004; 44:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/54\">",
"      Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106:3343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/55\">",
"      Covic A, Cannata-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008; 23:3731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/56\">",
"      Macdougall IC. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. Curr Opin Investig Drugs 2008; 9:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/57\">",
"      Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006; 34:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/58\">",
"      Woodburn KW, Fan Q, Winslow S, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/59\">",
"      Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009; 361:1848.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM297628.pdf.",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/62\">",
"      Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis 2012; 59:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/63\">",
"      Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013; 368:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8265/abstract/64\">",
"      Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013; 368:320.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1930 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8265=[""].join("\n");
var outline_f8_4_8265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Eprex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Non-Eprex cases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SCREENING FOR ANTI-EPO ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bone marrow aspirate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anti-EPO antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Peginesatide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_4_8266="Vegetarian diets for children";
var content_f8_4_8266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vegetarian diets for children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8266/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8266/contributors\">",
"     Debby Demory-Luce, PhD, RD, LD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8266/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8266/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8266/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8266/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/4/8266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/4/8266/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/4/8266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vegetarian diets are becoming increasingly popular [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. A nationally representative study conducted in the United States in 2008 estimated that 10 percent (22.8 million) of Americans aged 18 and older follow a \"vegetarian-inclined\" diet, 3.2 percent (7.3 million) indicated that they follow a vegetarian diet, and 0.5 percent (1 million) follow a vegan diet [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/7\">",
"     7",
"    </a>",
"    ]. A poll conducted in the United States in 2006 estimated that 6.7 percent of Americans aged 18 and older do not eat meat, 2.3 percent do not eat meat, fish, or poultry, and 1.4 percent do not eat meat, fish, poultry, dairy products, or eggs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 5 percent of individuals in the United Kingdom, Germany, and Australia describe themselves as vegetarian [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increasing number of families are choosing to rear their children on a vegetarian eating style [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. An estimated 8 percent of adolescents in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/13\">",
"     13",
"    </a>",
"    ] and 6 percent of public middle- and high-school students surveyed in the midwestern United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/14\">",
"     14",
"    </a>",
"    ] consume a vegetarian diet. A poll conducted in 2005 estimated that 6 percent of American youth aged 8 to 18 years do not eat meat, 3 percent do not eat meat, fish, or poultry, and 1 percent do not eat meat, fish, poultry, dairy or eggs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of vegetarian diets are complicated by variations in definitions for the term \"vegetarian\". Definitions range from whether the individual considers himself or herself as vegetarian (\"self-defined\" vegetarians), avoids meat only, or lives by the strict definition (never consuming meat, fish, and poultry). As an example, one review of dietary patterns and nutrient intakes of self-defined vegetarians (aged six years and older) found that patterns ranged from those who consumed reduced amounts of red meat but included poultry and fish, to those who excluded all animal foods [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reasons for choosing a vegetarian diet are varied and include potential health benefits and sociopolitical, ecological, and ethical issues related to allocation of resources and animal rights [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/3,7,17-21\">",
"     3,7,17-21",
"    </a>",
"    ]. Adolescents pose a particular challenge because it may be difficult to determine if an adolescent's choice to become a vegetarian is related to dietary restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The types and composition of vegetarian diets also are varied and have important implications for the growth and development of children and adolescents.",
"   </p>",
"   <p>",
"    The nutritional quality of vegetarian diets and strategies to prevent nutritional deficiencies while consuming vegetarian diets are reviewed here. Nutrition requirements, deficiencies, and supplementation of specific nutrients are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF VEGETARIAN DIETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vegetarian diets vary according to the degree of avoidance of foods of animal origin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/18\">",
"     18",
"    </a>",
"    ]. According to the strictest definition, a vegetarian diet consists primarily of cereals, fruits, vegetables, legumes, and nuts; animal foods, including milk, dairy products, and eggs generally are excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. Several less restrictive vegetarian diets may include animal flesh, eggs, or milk and dairy products. Vegetarian diets frequently are grouped as follows (less to more restricted):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Semi-vegetarian &mdash; Meat occasionally is included in the diet. Some people who follow such a diet may not eat red meat but may eat fish and perhaps chicken.",
"     </li>",
"     <li>",
"      Lacto-ovovegetarian &mdash; Eggs, milk, and milk products (lacto = dairy; ovo = eggs) are included, but no meat is consumed.",
"     </li>",
"     <li>",
"      Lactovegetarian &mdash; Milk and milk products are included in the diet, but no eggs or meat are consumed.",
"     </li>",
"     <li>",
"      Macrobiotic &mdash; Whole grains, especially brown rice, are emphasized and vegetables, fruits, legumes, and seaweeds are included in the diet. Locally-grown fruits are recommended. Animal foods limited to white meat or white-meat fish may be included in the diet once or twice a week.",
"     </li>",
"     <li>",
"      Vegan &mdash; All animal products, including eggs, milk, and milk products, are excluded from the diet. Some vegans do not use honey and may refrain from using animal products such as leather or wool. They also may avoid foods that are processed or not organically grown [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vegetarian diets vary considerably, as do omnivorous diets. The nutritional adequacy of a vegetarian diet must be judged individually, not on the basis of what it is called but on the type, amount, and variety of nutrients that are consumed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term effects of a vegetarian diet on morbidity and mortality are difficult to separate from those of the vegetarian lifestyle (eg, regular exercise, avoidance of tobacco and alcohol products); however, consumption of a vegetarian diet is associated with lower incidence of obesity, coronary heart disease, hypertension, and type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/3,5,6,25-34\">",
"     3,5,6,25-34",
"    </a>",
"    ]. Overall, evidence suggests that being a lactovegetarian has greater health benefits and reduced health risks than being a vegan [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GROWTH OF VEGETARIAN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;When meal planning is adequate and diets are not inappropriately restricted, physical growth of vegetarian, even vegan, children is within the normal range, although vegetarian children tend to be leaner than their omnivore counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/3,11,12,36-38\">",
"     3,11,12,36-38",
"    </a>",
"    ]. By contrast, poorly planned or severely restricted diets can lead to nutrient deficiencies that may compromise or delay growth in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/36,39-43\">",
"     36,39-43",
"    </a>",
"    ]. As an example, Dutch investigators conducted a longitudinal anthropometric study in a population consuming a macrobiotic diet [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/43\">",
"     43",
"    </a>",
"    ]. Compared with the reference population, height and arm circumference were reduced for both boys and girls at all ages, despite the presence of catch-up growth as the children approached adolescence. Catch-up growth was related to the addition of dairy products to the diet.",
"   </p>",
"   <p>",
"    In comparison, other studies have demonstrated normal growth in children consuming different types of vegetarian diets:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 1765 children aged 7 to 18 years attending Southern California state schools and Seventh-day Adventist schools, the Adventist semi-vegetarian children (those consuming meat less than once per week) were taller on average than their meat-eating classmates (2.5 and 2.0 cm for boys and girls, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 82 lactoovovegetarian children, adolescents, and young adults, the mean height and weight of the children and young adults did not differ from those of the reference population [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/11\">",
"       11",
"      </a>",
"      ]. Male adolescents had lower height, weight, and body mass index; female adolescents had lower weight and body mass index than did the reference population. Menarche occurred at a normal age.",
"     </li>",
"     <li>",
"      Anthropometric data were collected on 404 vegan children, aged 4 months to 10 years, on a collective farm in Tennessee [",
"      <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/38\">",
"       38",
"      </a>",
"      ]. The mean height age and weight age of the vegan children were slightly less than the median of the reference population (0.1 standard deviation for height and 0.3 standard deviation for weight), although the height and weight for age were normal in most children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NUTRITIONAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest risks associated with inadequate nutrient intake from a vegetarian diet occur during periods of growth. The more restrictive the vegetarian diet, the greater the risk of dietary inadequacy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/3,44,45\">",
"     3,44,45",
"    </a>",
"    ]. Vegetarian diets can meet nutrient needs for growth and development if they are carefully planned with attention to the following possible limiting nutrients: energy, protein, iron, zinc, calcium, vitamin D, vitamin B12 (cyanocobalamin), long-chain omega-3 fatty acids, and dietary fiber, as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/2,5,19,46-49\">",
"     2,5,19,46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The establishment of healthy eating patterns in childhood reduces the likelihood of developing chronic diseases later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/25,50-55\">",
"     25,50-55",
"    </a>",
"    ]. Thus, vegetarian children, like other children, should consume a diet low in fat, saturated fatty acids, and cholesterol, and high in complex carbohydrates, fiber, and antioxidants (eg, vitamins C and A, carotenoids, and phytochemicals) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/18,25,48,51,56,57\">",
"     18,25,48,51,56,57",
"    </a>",
"    ]. In one survey of self-reported dietary intake in 4746 adolescent school children in Minnesota, the percentage of those meeting the Healthy People 2010 nutritional objectives were compared with vegetarians and nonvegetarians [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/58\">",
"     58",
"    </a>",
"    ]. Adolescents who identified themselves as vegetarians were more likely than nonvegetarians to meet the objectives for total fat (70 versus 48 percent), saturated fat (65 versus 39 percent), daily servings of vegetables (26 versus 14 percent), and &ge;5 servings of fruits or vegetables per day (39 versus 28 percent). The mean calcium intake in both groups (approximately 1100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was less than recommended, and only 30 percent of the students, regardless of dietary group, ingested the recommended 1300",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Eating disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although adolescents may experience the health benefits of a vegetarian diet, in some individuals the vegetarian diet is a manifestation of dietary restriction and other disordered eating behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/14,23,59\">",
"     14,23,59",
"    </a>",
"    ]. In one report, current adolescent vegetarians were more likely than nonvegetarians to report binge eating, and vegetarians were more likely than nonvegetarians to engage in unhealthy weight control behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Energy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children need adequate energy for growth and development. If energy intake is not sufficient, meeting essential nutrient needs is difficult, and proteins are broken down for energy instead of for growth and repair [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/11,53,61\">",
"     11,53,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23735?source=see_link\">",
"     \"Dietary energy requirements in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who follow vegetarian diets, particularly vegan diets, may have difficulty consuming adequate amounts of energy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/11,12,36,62\">",
"     11,12,36,62",
"    </a>",
"    ]. A plant-based diet that has a high fiber content and low caloric density may provide a sense of fullness before an adequate amount of energy is ingested. This situation may be a significant problem in young children, who have small stomach capacities.",
"   </p>",
"   <p>",
"    Adolescents who follow a vegetarian diet as a means of weight management should be monitored closely for evidence of an eating disorder and given anticipatory guidance to ensure adequate dietary energy intake [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/22\">",
"     22",
"    </a>",
"    ]. To support appropriate weight gain, dietary variety should be emphasized, and foods should be relatively high in energy density without significant bulk. A Vegetarian Food Guide Pyramid depicting food groups and portion sizes may serve as a useful reference guide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/24,48\">",
"     24,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that children and adolescents eat frequent meals and snacks containing energy and nutrient-dense foods to meet their energy needs. Examples of such foods include cooked legumes, whole grain breads, enriched cereals, nuts, and nut spreads (peanut, tahini, almond, and cashew butter), nutlike seeds (sunflower seeds, soybeans, sesame seeds), avocados, and dried fruits. In addition, the inclusion of dairy products in the vegetarian diet provides a substantial portion of essential nutrients. Dairy products are good sources of energy, protein, calcium, potassium, and magnesium [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For adolescents who choose to adopt a vegetarian diet, the clinician should inquire about what prompted a change in the diet, recognizing that the developmental period, as well as family preferences, may have played a role in his or her dietary choice. The clinician should ensure that the adolescent and the family have access to accurate nutritional resources and that dietary changes were not based on underlying emotional problems, including an eating disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/22\">",
"     22",
"    </a>",
"    ]. Any adolescent whose body mass index (BMI) is less than the 15th percentile, or whose actual weight is less than 85 percent of the expected weight for height and age,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who has other features suggestive of an eating disorder (including disrupted menses or body image disturbances) is a candidate for referral for more intensive medical and psychological care. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Eating disorders'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vegetarian diets generally are rich in omega-6 (n-6) fatty acids, but marginal in omega-3 (n-3) fatty acids, unless the diet includes fish, eggs, or generous amounts of algae. Omega-3 fatty acids, which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or their precursor alpha-linolenic acid (ALA), are important for cardiovascular health and eye and brain development. Vegetarians, particularly vegans, have lower blood levels of EPA and DHA than nonvegetarians [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/5,63\">",
"     5,63",
"    </a>",
"    ]. Dietary requirements for n-3 fatty acids in infants, children, and adolescents have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescent vegetarians who do not eat oily fish should include good sources of alpha-linolenic acid in their diet, such as flaxseed, walnuts, canola oil, and soy. Soy milk and breakfast bars, fortified with DHA, also are available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein requirements for children are approximately 1.05",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    for those one to three years of age, 0.95",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    for those 4 to 13 years of age, and 0.85",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    for adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protein quality of a diet helps determine how well a diet supports the nutritional needs and growth of children. Protein quality is determined primarily by amino acid composition; digestibility also has an influence on protein quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Amino acid composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The important difference between proteins of plant and animal origin is the concentration of essential amino acids they contain; essential amino acids are necessary for growth and repair. Animal foods are considered complete or high-quality proteins because they contain all nine essential amino acids. Plant-based foods are usually incomplete, meaning they are deficient in one or more of the essential amino acids. Several approaches can be used to correct this deficiency: addition of milk or eggs, use of soybean products, use of complementary foods, and ingestion of protein-rich foods.",
"   </p>",
"   <p>",
"    Soybean-based products are essentially equivalent in quality to animal protein and are an important source of protein for vegetarians [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/65\">",
"     65",
"    </a>",
"    ]. However, young infants have a relatively high nutritional requirement for essential amino acids, and soybeans are deficient in methionine. Supplementation of soy-based formulas with methionine may improve the utilization of soy protein by infants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The need for essential amino acids decreases as growth and development progress. Thus, soy protein isolates without methionine supplementation can serve as a primary source of essential amino acids and nitrogen for protein maintenance in children older than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The essential amino acid deficit of one plant food can be overcome by combining it with a complementary plant food that provides adequate amounts of the limited essential amino acid. As an example, grains are low in the essential amino acid lysine and high in methionine, whereas legumes are low in methionine and high in lysine. Together, they combine to make a high-quality protein source. One need not consume complementary proteins at the same time or in the same meal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/68\">",
"     68",
"    </a>",
"    ]. The adequacy of protein intake is determined by the total quantity of protein and amino acids from the variety of foods consumed during the day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Digestibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, amino acids from animal sources are most easily digested (over 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/45\">",
"     45",
"    </a>",
"    ]. Well-processed soy isolates are as digestible as egg protein [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/70\">",
"     70",
"    </a>",
"    ]. Amino acids from legumes is 80 to 90 percent digestible. Proteins from grains and other plant foods are less digestible (70 to 90 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children fed vegetarian diets that also include animal flesh, milk, milk products, or eggs generally consume more than enough complete protein to meet their needs as long as energy intake is sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/53\">",
"     53",
"    </a>",
"    ]. Meat and fish are good sources of protein for children who consume semi-vegetarian or macrobiotic diets. Non-meat foods high in protein include soy products (eg, tofu and soy milk), milk, other dairy products, and eggs. Foods such as legumes, grains, cereals, potatoes, and pasta also contribute to protein intake but to a lesser degree.",
"   </p>",
"   <p>",
"    If vegan children eat a variety of plant foods and meet caloric needs, their protein intake is usually adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/2,5,16,53,68\">",
"     2,5,16,53,68",
"    </a>",
"    ]. However, because of the lower digestibility of plant proteins, vegan children whose dietary protein sources consist of mainly those that are less digested, such as cereals and legumes, protein requirements may be increased by 20 to 30 percent for children aged two to six years and 15 to 20 percent for children aged six and older in comparison with nonvegetarians [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have rapid growth rates have increased iron needs and are at risk for iron deficiency with or without anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/71\">",
"     71",
"    </a>",
"    ]. The RDA for iron is 7 mg in children 1 to 3 years, 10 mg in children 4 to 8 years, 8 mg in children 9 to 13 years, and 11 mg for boys and 15 mg for girls age 14 to 18 years. The value is increased to 27",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    for pregnant adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns about iron nutrition for vegetarian children center on differences between heme (meat) and nonheme (plant) iron [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/47,71-74\">",
"     47,71-74",
"    </a>",
"    ]. Heme iron is more readily absorbed than is nonheme iron (15 to 35 percent versus 2 to 20 percent, respectively). In addition, the absorption of nonheme iron is reduced greatly by other dietary components, whereas heme iron is little affected (",
"    <a class=\"graphic graphic_table graphicRef64874 \" href=\"UTD.htm?26/5/26715\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tannins and polyphenols in tea and coffee form iron-tannate complexes that greatly reduce nonheme iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/71,75\">",
"     71,75",
"    </a>",
"    ]. Phytate found in legumes, nuts, seeds, whole grains, and soy protein also bind with nonheme iron to form insoluble complexes and reduce iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/71,76-78\">",
"     71,76-78",
"    </a>",
"    ]. In one study, absorption of iron from a variety of commonly eaten legumes (dried beans and peas) prepared as soups was only 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because milk and eggs are not good sources of absorbable iron, vegetarian children, including lacto-ovovegetarians, are at greater risk for iron deficiency than are their omnivorous peers; children who consume restricted vegetarian diets are at greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/45,71,79,80\">",
"     45,71,79,80",
"    </a>",
"    ]. As an example, one study of 39 vegetarian children found hematological indices that were suggestive of mild iron deficiency anemia in 25 percent, predominantly in macrobiotic vegetarians [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/81\">",
"     81",
"    </a>",
"    ]. In a study of 1100 children aged 4 to 18 years, female adolescents who reported being vegetarian were more likely to have low hemoglobin and serum ferritin values than their omnivorous peers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Avoidance of large intakes of tannin-containing teas, supplementation with ascorbic acid (vitamin C), and increasing dietary iron content are three strategies used to increase iron absorption in children consuming vegetarian diets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/71,82-85\">",
"     71,82-85",
"    </a>",
"    ]. Good plant sources of iron include whole or enriched breads or grains, iron-fortified cereals, legumes, green leafy vegetables, dried fruits, soy products, blackstrap molasses, bulgur, and wheat germ. The widespread fortification of enriched breads, cereals, and pasta products has helped increase iron intake for children.",
"   </p>",
"   <p>",
"    Ascorbic acid, which prevents the formation of less soluble ferric compounds, is a powerful promoter of nonheme iron absorption and can counteract the inhibitory effect of phytates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/79,86-88\">",
"     79,86-88",
"    </a>",
"    ]. A 75 mg dose of ascorbic acid increases the absorption of nonheme iron by three- to fourfold [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/76\">",
"     76",
"    </a>",
"    ]. Because of its mechanism of action, ascorbic acid is effective only when consumed with iron-containing food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend a source of ascorbic acid be included at each meal to enhance the absorption of non-heme iron [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/71,79,86\">",
"     71,79,86",
"    </a>",
"    ]. Fruits and vegetables such as citrus fruits, strawberries, broccoli, and tomatoes are important sources of both vitamin C and other facilitators of iron absorption (eg, citric and malic acid).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for zinc are 3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for children aged 1 to 3 years, 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for children aged 4 to 8 years, and 8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for children aged 9 to 13 years. For adolescent females and males aged 14 to 18 years, the recommendations are 9",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and 11",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    respectively (",
"    <a class=\"graphic graphic_table graphicRef51953 \" href=\"UTD.htm?37/22/38241\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Zinc is found in foods of both animal and plant origin. Animal sources include oysters, shellfish, liver, meat, poultry, and dairy products [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/47,89\">",
"     47,89",
"    </a>",
"    ]. Milk and milk products are the primary source of zinc for children on vegetarian diets who also consume animal products. Good plant sources include whole grains, legumes, wheat germ, and nuts. Cereals are the primary source of zinc for children who consume vegetarian diets without milk; secondary sources are meat substitutes (eg, legumes, nuts, and soy products).",
"   </p>",
"   <p>",
"    Food preparation techniques, such as soaking of sprouting beans, grains, and seeds as well as leavening breads, can reduce binding of zinc by phytates and increase zinc bioavailability [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/2,5,90,91\">",
"     2,5,90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The zinc in vegetarian diets has a lower bioavailability because of the high content of phytate and dietary fiber [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/45,56,80,92\">",
"     45,56,80,92",
"    </a>",
"    ]. Adult vegetarians do not typically develop zinc deficiency because they have a compensatory increase in fractional absorption. Children may be at greater risk of a suboptimal zinc status because of high requirements for growth. Zinc deficiency can be associated with growth impairment and an increased risk of infections, particularly diarrhea and pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of adequate calcium intake is important throughout life to ensure peak bone mass accumulation, especially during periods of growth. Children with stronger bones may experience fewer fractures and may be more resistant to the development of osteoporosis in later life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. The optimal daily dietary allowance of calcium for children and adolescents is somewhat controversial but probably approximates 500 mg for children 1 to 3 years of age, 800 mg for children 4 to 8 years of age, and 1300 mg for those 9 to18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link\">",
"     \"Calcium requirements in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium intake may need to be increased to overcome the effects of other dietary constituents that decrease calcium absorption (oxalate and phytate) or increase excretion (salt and protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/85,96,98\">",
"     85,96,98",
"    </a>",
"    ]. The diminished intake of animal protein by vegetarians may help their net calcium balance by decreasing urinary calcium loss. Animal protein, with sulfur-containing amino acids, produces an increased acid load and decreases renal tubular calcium reabsorption (",
"    <a class=\"graphic graphic_figure graphicRef56597 \" href=\"UTD.htm?24/29/25053\">",
"     figure 1",
"    </a>",
"    ). Animal protein intake also increases uric acid excretion and reduces urinary citrate excretion; all of these changes tend to promote calcium stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H22#H22\">",
"     \"Risk factors for calcium stones in adults\", section on 'Protein'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the calcium needs of children who consume lactovegetarian or lactoovovegetarian diets can be met by low-fat milk and dairy products that provide approximately 75 percent of the calcium in the average American diet [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/96,100,101\">",
"     96,100,101",
"    </a>",
"    ]. Vegan children have more difficulty meeting calcium needs because they avoid dairy products, which contain more calcium than vegetables, fruit, and cereal grains [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/46\">",
"     46",
"    </a>",
"    ]. Therefore, the calcium intake of children who consume vegan diets is generally lower than that of lacto-ovovegetarians and omnivores [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Vegan children can obtain calcium from foods naturally rich in calcium, calcium-fortified foods and beverages, calcium supplements, or a combination of these.",
"   </p>",
"   <p>",
"    The following foods are naturally rich in calcium and low in oxalate: kale, mustard greens, turnip greens, broccoli, bok choy, dried figs, blackstrap molasses, and lime-processed tortillas (",
"    <a class=\"graphic graphic_table graphicRef52445 \" href=\"UTD.htm?34/25/35229\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/96\">",
"     96",
"    </a>",
"    ]. However, to meet calcium requirements from these foods alone would be difficult, even with large portions.",
"   </p>",
"   <p>",
"    Calcium-fortified foods include soy milk, soy yogurt, and soy cheese, as well as calcium precipitated tofu and calcium-fortified cereals, breakfast bars, pastas, waffles, and juices [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/57,105\">",
"     57,105",
"    </a>",
"    ]. Calcium bioavailability in most of these sources is equivalent to milk. As an example, one eight-ounce glass of calcium-fortified orange juice provides 300 mg of calcium, equivalent to an eight-ounce glass of milk. In contrast, the bioavailability of calcium in soy milk is only 75 percent of that in cow's milk [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of increasing calcium intake with fortified foods was demonstrated in a double-blind-placebo-controlled study of prepubertal girls with low spontaneous calcium intake who were randomly assigned to receive food products that were or were not fortified with 850 mg of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/107\">",
"     107",
"    </a>",
"    ]. Calcium fortification increased mean bone mineral density in all girls, but the increase was greatest in those who had spontaneous calcium intakes less than 850 mg. The gains in bone mass were present one year after discontinuation of treatment.",
"   </p>",
"   <p>",
"    Calcium supplements also can be used to provide adequate calcium intake. However, foods rich in or fortified with calcium are preferred because they provide additional nutrients that are important for growth and development. Consuming calcium supplements at the same time as iron or zinc supplements may interfere with the absorption and utilization of these minerals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link\">",
"     \"Calcium requirements in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend vegetarian children who do not drink milk receive at least one calcium-rich or fortified food at each meal and several snacks to provide a calcium intake of 500 mg per day for children one to three years, 800 mg per day if they are four to eight years, and 1300 mg per day if they are nine years and older. Children who are unable to meet these goals with calcium-rich foods should take a calcium supplement. The milk alternative should also be fortified with vitamin D because vitamin D facilitates the absorption of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal levels of vitamin D metabolites are necessary for adequate intestinal calcium, phosphate absorption, and bone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Vitamin D availability is a function of sunlight exposure and dietary intake (",
"    <a class=\"graphic graphic_figure graphicRef65360 \" href=\"UTD.htm?20/23/20862\">",
"     figure 2",
"    </a>",
"    ). Maintenance of normal serum vitamin D concentrations requires exposure to the sun on hands, arms, and face for 10 to 15 minutes per day for fair-skinned individuals; individuals with dark skin pigmentation require 6 to 10 times as much exposure as a light-skinned individual [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/110\">",
"     110",
"    </a>",
"    ]. In addition to sun exposure, a dietary intake of 600 IU generally is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H23365817#H23365817\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Recommendations for vitamin D intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few foods contain vitamin D. The principal dietary source of vitamin D for omnivores, lacto-ovovegetarians, and lactovegetarians is milk fortified with vitamin D (100 IU per 8 oz) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/48\">",
"     48",
"    </a>",
"    ]. Vegetarians who do not consume milk are at risk for vitamin D deficiency and rickets in children and osteomalacia in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/111-114\">",
"     111-114",
"    </a>",
"    ]. In one study of 53 children (one to two years of age) on a macrobiotic diet compared with 57 matched omnivores, symptoms of rickets were present in 28 percent of the macrobiotic children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/115\">",
"     115",
"    </a>",
"    ]. A dietary alternative for these children is soy milk or breakfast cereal fortified with calcium and vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/56,93\">",
"     56,93",
"    </a>",
"    ]. Fatty fishes (sardines, salmon, tuna, mackerel) and cod liver oils are some of the better food sources of vitamin D. Beef liver, cheese, and egg yolks provide small amounts of vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of vitamin D\", section on 'Sources'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D supplementation should be used for children without adequate sunlight exposure or dietary intake from enriched foods, particularly during the winter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/57,93,116\">",
"     57,93,116",
"    </a>",
"    ]. During the winter months, the consumption of fatty fish several times per week can provide sufficient vitamin D for children consuming a macrobiotic diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vitamin B12",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin B12 (cobalamin) is only found in foods from animal sources (meat, fish, eggs, and dairy products) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/48,116\">",
"     48,116",
"    </a>",
"    ]. The RDA for cobalamin is 0.9 mcg for children 1 to 3 years of age, 1.2 mcg for those 4 to 8 years, 1.8 mcg for 9 to 13 years, 2.4 mcg for 14 to 18 years, and 2.6 mcg for pregnant adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lacto-ovovegetarians and lactovegetarians can, but do not always, consume sufficient amounts of vitamin B12 from eggs, milk, and milk products. Vegans, whose diets are based entirely on plant food, are at considerable risk for vitamin B12 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/57,102,116,118,119\">",
"     57,102,116,118,119",
"    </a>",
"    ]. For example, in one study,10 of 25 vegans had vitamin B12 deficiency manifested by macrocytosis (",
"    <a class=\"graphic graphic_picture graphicRef74901 \" href=\"UTD.htm?9/45/9942\">",
"     picture 1",
"    </a>",
"    ) and low serum vitamin B12 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/120\">",
"     120",
"    </a>",
"    ]. In another report, serum vitamin B12 concentrations were determined in 83 volunteer subjects attending an American vegetarian society conference [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/121\">",
"     121",
"    </a>",
"    ]. In subjects who did not supplement their diets with vitamin B12 or multivitamin tablets, the percentage with serum vitamin B12 levels below the normal range was a function of the dietary restriction:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vegans &mdash; 92 percent",
"     </li>",
"     <li>",
"      Lactovegetarians &mdash; 64 percent",
"     </li>",
"     <li>",
"      Lacto-ovovegetarians &mdash; 47 percent",
"     </li>",
"     <li>",
"      Semi-vegetarians &mdash; 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vegan children and other vegetarians whose diet does not contain adequate vitamin B12 should consume a regular and reliable source of the vitamin, either in fortified foods or an oral B12 supplement providing 6 to 9 mcg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/47,62\">",
"     47,62",
"    </a>",
"    ]. Some listings of vitamin B12 content do not differentiate between the vitamin and its inactive analogs. Much of the vitamin B12 present in spirulina, sea vegetables, tempeh, and miso is inactive and can compete with active forms for absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/105,122\">",
"     105,122",
"    </a>",
"    ]. The food nutrition label should list the content of cyanocobalamin, the active form of the vitamin.",
"   </p>",
"   <p>",
"    Commonly used B12-fortified foods include certain brands of nutritional yeasts, most ready-to-eat cereals, many meat analogs, and some milk alternatives [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/16\">",
"     16",
"    </a>",
"    ]. Fortified soy milk is a good source of B12 for children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vegetarians often have high dietary fiber intake. In one study of 51 adults, omnivores consumed the least fiber (23 g), vegetarians significantly more (37 g), and vegans the most (47 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/124\">",
"     124",
"    </a>",
"    ]. In a similar study of 106 children 6 to 16 months of age, mean daily fiber intake was greater in those following a macrobiotic diet than in omnivores (13 versus 7 grams) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/125\">",
"     125",
"    </a>",
"    ]. The consumption of a high-fiber diet in childhood promotes normal laxation and possibly reduces the risk of developing certain diseases in adulthood. However, a childhood diet too high in fiber can compromise dietary energy intake and, as noted above, reduce the bioavailability of minerals such as iron, calcium, and zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/45,47,126\">",
"     45,47,126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimum level of dietary fiber for infants and children younger than 2 years of age is not known. Studies of weaning diets with increased fiber found no negative effect on the absorption of energy, zinc, and calcium or iron bioavailability and suggested 5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. However, other studies have shown that growth is poor among infants and toddlers weaned onto very high-fiber, low-calorie diets that often are deficient in vitamins and minerals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/104,129\">",
"     104,129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small loss of energy, primarily as fat, and protein may occur with a high intake of dietary fiber. Daily fecal energy loss is estimated to increase by 1 percent for every 6-gram increase in dietary fiber. This loss is unlikely to be significant in children who consume adequate energy.",
"   </p>",
"   <p>",
"    For children aged one to three years, the recommended fiber intake should be 19",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    For children aged four to eight years, the recommended fiber intake should be 25",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    For children aged 9 to 13 years, the recommended fiber intake ranges from 26 to 31",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    This amount of dietary fiber should not have an adverse effect on mineral bioavailability, provided the dietary mineral intake is adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/61\">",
"     61",
"    </a>",
"    ]. Intake of fiber that exceeds the recommendation is unlikely to decrease mineral bioavailability in vegetarian children who consume a balanced diet from a variety of foods, but may be problematic in children who follow strict macrobiotic or vegan diets with low intake of calcium, iron, and zinc. Studies of children younger than 10 years of age who consumed a macrobiotic diet based mainly on whole-grain cereals and vegetables revealed deficiencies of energy, protein, vitamins, and minerals, resulting in retarded growth and slower psychomotor development [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fiber supplements are not recommended to meet dietary fiber goals. The dietary fiber goals can be met best by eating a variety of fiber-rich fruits, vegetables, cereals, and grain products while consuming adequate energy intake for growth and development [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children can safely ingest planned vegetarian diets and attain normal growth and development [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/2,5,130\">",
"     2,5,130",
"    </a>",
"    ]. A review of the composition of the individual diet is important to ensure adequate provision of energy, vitamins, and minerals. A supportive, nonjudgmental approach is important in establishing a relationship that will result in the parents' willingness to accept suggestions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/4/8266/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is possible to get complete balanced nutrition from a variety of vegetarian diets. More restrictive diets (eg, vegan) require particular care to ensure that all nutritional needs are met. Overall, a lactovegetarian diet has greater health benefits and reduced health risks than a vegan diet. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of vegetarian diets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some adolescents choose a vegetarian diet as a means of weight control, and clinicians should be alert for evidence of inappropriate dietary restriction and other disordered eating behaviors. An adolescent whose BMI is less than the 15th percentile, or whose actual weight is less than 85 percent of ideal body weight, is a candidate for referral for more intensive medical and psychological care. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nutritional considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Energy &mdash; The small stomach capacity of young children combined with low-caloric density foods may limit energy intake. To meet energy needs, children need three meals and three snacks per day. Both energy",
"      <strong>",
"       -",
"      </strong>",
"      and nutrient-dense foods should be included. The intake of fat should not be restricted in children younger than 2 years of age. For older children, some foods higher in unsaturated fats, such as nuts, seeds, nut and seed butters, and avocado, should be included to help meet nutrient and energy needs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Energy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Omega-3 fatty acids &mdash; Vegetarian diets generally are rich in omega-6 (n-6) fatty acids, but marginal in omega-3 (n-3) fatty acids, which are important for cardiovascular health and eye and brain development. Vegetarians should include good sources of alpha-linolenic acid in their diet, such as flaxseed, walnuts, canola oil, and soy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Omega-3 fatty acids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Protein &mdash; Intake of essential amino acids may be a problem for infants if intake is limited to plant-based low-quality protein products. Protein intake should be adequate if vegan children eat a variety of complementary plant foods to meet caloric needs. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iron &mdash; Heme (meat) iron is more readily absorbed than is non-heme iron, the absorption of which is adversely affected by other dietary constituents. Growing children who consume only non-heme iron are at risk of iron deficiency. A source of ascorbic acid should be provided at each meal to significantly enhance the absorption of non-heme iron. Teas containing tannin should be limited. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Iron'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Zinc &mdash; The zinc in vegetarian diets has a lower bioavailability than that in omnivorous diets because of the high content of phytate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dietary fiber. The clinical importance of reduced intake in vegan children is not known. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Zinc'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcium &mdash; Milk and other dairy products provide approximately 75 percent of the calcium in the average American diet. Vegetarian children who do not drink milk should receive at least one calcium-rich or fortified food at each meal and with several snacks each day to provide a daily calcium intake that approximates 500 mg for children 1 to 3 years, 800 mg if they are 4 to 8 years, and 1300 mg if they are 9 years and older. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Calcium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin D &mdash; Most foods do not contain any vitamin D. The principal dietary source of vitamin D for omnivores, lacto-ovovegetarians, and lactovegetarians is fortified milk. A vitamin D intake of 600",
"      <span class=\"nowrap\">",
"       IU/day",
"      </span>",
"      is necessary for adequate calcium balance. This balance can be provided by using soy milk or breakfast cereal fortified with calcium and vitamin D. Fatty fish can provide a source of vitamin D for macrobiotic children, particularly during winter. Vitamin D supplementation should be used for children without adequate sunlight exposure or dietary intake from enriched foods. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Vitamin D'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin B12 &mdash; Animal products (meat and dairy products) provide the only dietary source of vitamin B12 (cobalamin) for humans. Vegan children and other vegetarians whose diets do not contain adequate vitamin B12 should consume a regular and reliable source of the vitamin, either fortified foods (soy milk or cereals) or an oral B12 supplement. Provision of fish two to three times per week can provide a source of vitamin B12 for macrobiotic children. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Vitamin B12'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fiber &mdash; Fiber intake for children should be age-appropriate and approximate the currently recommended DRI. The mineral content of the diet should be adequate. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Fiber'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6020875\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Craig Jensen, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Stahler C. How many adults are vegetarian? The Vegetarian Resource Group asked in a 2006 national poll. Vegetarian J 2006: Issue 4 file://www.vrg.org/journal/vj2006issue4/vj2006issue4poll.htm (Accessed on March 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/2\">",
"      American Dietetic Association, Dietitians of Canada. Position of the American Dietetic Association and Dietitians of Canada: Vegetarian diets. J Am Diet Assoc 2003; 103:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/3\">",
"      Phillips F. Vegetarian nutrition. Nutr Bull 2005; 30:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/4\">",
"      Dunham L, Kollar LM. Vegetarian eating for children and adolescents. J Pediatr Health Care 2006; 20:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/5\">",
"      Craig WJ, Mangels AR, American Dietetic Association. Position of the American Dietetic Association: vegetarian diets. J Am Diet Assoc 2009; 109:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/6\">",
"      Craig WJ. Health effects of vegan diets. Am J Clin Nutr 2009; 89:1627S.",
"     </a>",
"    </li>",
"    <li>",
"     Vegetarian Times. Vegetarian Times study shows 7.3 million Americans are vegetarian. Vegetarian Times, 2008. file://www.vegetariantimes.com/features/archive_of_editorial/667 (Accessed on August 14, 2011).",
"    </li>",
"    <li>",
"     Gallup. The Realat Survey 1997. Changing attitudes to meat consumption. Haldane Food, 1997.",
"    </li>",
"    <li>",
"     Allensbach Population Survey Institute. Allensbach, Germany: Allensbach Institute for Demoscopy, August, 1996.",
"    </li>",
"    <li>",
"     McLennan W, Podger A. National Nutrition Survey&mdash;Selected highlights in Australia. Australian Bureau of Statistics, Canberra, Australia 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/11\">",
"      Hebbelinck M, Clarys P, De Malsche A. Growth, development, and physical fitness of Flemish vegetarian children, adolescents, and young adults. Am J Clin Nutr 1999; 70:579S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/12\">",
"      Nathan I, Hackett AF, Kirby S. A longitudinal study of the growth of matched pairs of vegetarian and omnivorous children, aged 7-11 years, in the north-west of England. Eur J Clin Nutr 1997; 51:20.",
"     </a>",
"    </li>",
"    <li>",
"     Vegetarian Society, UK. Trends in vegetarianism among adults and young people. Vegetarian Society, Altrincham, United Kingdom 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/14\">",
"      Perry CL, Mcguire MT, Neumark-Sztainer D, Story M. Characteristics of vegetarian adolescents in a multiethnic urban population. J Adolesc Health 2001; 29:406.",
"     </a>",
"    </li>",
"    <li>",
"     Stahler, C. How many youth are vegetarian? The Vegetarian Resource Group asked in a 2005 national poll. Vegetarian J 2005; Issue 4. Available at: file://www.vrg.org/journal/vj2005issue4/vj2005issue4youth.htm (Accessed on August 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/16\">",
"      Haddad EH, Tanzman JS. What do vegetarians in the United States eat? Am J Clin Nutr 2003; 78:626S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/17\">",
"      Lea E, Worsley A. The cognitive contexts of beliefs about the healthiness of meat. Public Health Nutr 2002; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     Leitzmann C. Vegetarian diets: what are the advantages? Forum Nutr 2005:147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/19\">",
"      Johnston PK, Haddad E, Sabate J. The Vegetarian Adolescent. Adolesc Med 1992; 3:417.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston PK, Sabate J. Nutritional implications of vegetarian diets. In: Modern nutrition in health and disease, 10, Shils ME, Shike M, Ross AC, et al (Eds), Lippincott Williams &amp; Wilkins, Baltimore 2006. p.1638.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/21\">",
"      Fox N, Ward K. Health, ethics and environment: a qualitative study of vegetarian motivations. Appetite 2008; 50:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/22\">",
"      Renda M, Fischer P. Vegetarian diets in children and adolescents. Pediatr Rev 2009; 30:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/23\">",
"      Greene-Finestone LS, Campbell MK, Evers SE, Gutmanis IA. Attitudes and health behaviours of young adolescent omnivores and vegetarians: a school-based study. Appetite 2008; 51:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/24\">",
"      Haddad EH, Sabat&eacute; J, Whitten CG. Vegetarian food guide pyramid: a conceptual framework. Am J Clin Nutr 1999; 70:615S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/25\">",
"      Key TJ, Fraser GE, Thorogood M, et al. Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. Am J Clin Nutr 1999; 70:516S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/26\">",
"      Deckelbaum RJ, Fisher EA, Winston M, et al. Summary of a scientific conference on preventive nutrition: pediatrics to geriatrics. Circulation 1999; 100:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/27\">",
"      Fraser GE. Associations between diet and cancer, ischemic heart disease, and all-cause mortality in non-Hispanic white California Seventh-day Adventists. Am J Clin Nutr 1999; 70:532S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/28\">",
"      Mezzano D, Mu&ntilde;oz X, Mart&iacute;nez C, et al. Vegetarians and cardiovascular risk factors: hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost 1999; 81:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/29\">",
"      Lila MA. From beans to berries and beyond: teamwork between plant chemicals for protection of optimal human health. Ann N Y Acad Sci 2007; 1114:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/30\">",
"      Rao V, Al-Weshahy A. Plant-based diets and control of lipids and coronary heart disease risk. Curr Atheroscler Rep 2008; 10:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/31\">",
"      Barnard ND, Katcher HI, Jenkins DJ, et al. Vegetarian and vegan diets in type 2 diabetes management. Nutr Rev 2009; 67:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/32\">",
"      Craig WJ. Nutrition concerns and health effects of vegetarian diets. Nutr Clin Pract 2010; 25:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/33\">",
"      Farmer B, Larson BT, Fulgoni VL 3rd, et al. A vegetarian dietary pattern as a nutrient-dense approach to weight management: an analysis of the national health and nutrition examination survey 1999-2004. J Am Diet Assoc 2011; 111:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/34\">",
"      Crowe FL, Appleby PN, Travis RC, Key TJ. Risk of hospitalization or death from ischemic heart disease among British vegetarians and nonvegetarians: results from the EPIC-Oxford cohort study. Am J Clin Nutr 2013; 97:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/35\">",
"      Weaver CM. Should dairy be recommended as part of a healthy vegetarian diet? Point. Am J Clin Nutr 2009; 89:1634S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/36\">",
"      Sanders TA, Manning J. The growth and development of vegan children. J Hum Nutr Diet 1992; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/37\">",
"      Sabat&eacute; J, Lindsted KD, Harris RD, Sanchez A. Attained height of lacto-ovo vegetarian children and adolescents. Eur J Clin Nutr 1991; 45:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/38\">",
"      O'Connell JM, Dibley MJ, Sierra J, et al. Growth of vegetarian children: The Farm Study. Pediatrics 1989; 84:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/39\">",
"      Dwyer JT, Andrew EM, Valadian I, Reed RB. Size, obesity, and leanness in vegetarian preschool children. J Am Diet Assoc 1980; 77:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/40\">",
"      Shull MW, Reed RB, Valadian I, et al. Velocities of growth in vegetarian preschool children. Pediatrics 1977; 60:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/41\">",
"      Fulton JR, Hutton CW, Stitt KR. Preschool vegetarian children. Dietary and anthropometric data. J Am Diet Assoc 1980; 76:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/42\">",
"      Dagnelie PC, van Staveren WA, van Klaveren JD, Burema J. Do children on macrobiotic diets show catch-up growth? A population-based cross-sectional study in children aged 0-8 years. Eur J Clin Nutr 1988; 42:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/43\">",
"      Van Dusseldorp M, Arts IC, Bergsma JS, et al. Catch-up growth in children fed a macrobiotic diet in early childhood. J Nutr 1996; 126:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/44\">",
"      Johnston PK. Vegetarians among us: Implications for health professionals. Top Clin Nutr 1995; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/45\">",
"      Messina V, Mangels AR. Considerations in planning vegan diets: children. J Am Diet Assoc 2001; 101:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/46\">",
"      Larsson CL, Johansson GK. Dietary intake and nutritional status of young vegans and omnivores in Sweden. Am J Clin Nutr 2002; 76:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/47\">",
"      Murphy SP, Allen LH. Nutritional importance of animal source foods. J Nutr 2003; 133:3932S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/48\">",
"      Venti CA, Johnston CS. Modified food guide pyramid for lactovegetarians and vegans. J Nutr 2002; 132:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/49\">",
"      Ambroszkiewicz J, Klemarczyk W, Gajewska J, et al. Serum concentration of biochemical bone turnover markers in vegetarian children. Adv Med Sci 2007; 52:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/50\">",
"      Key TJ, Davey GK, Appleby PN. Health benefits of a vegetarian diet. Proc Nutr Soc 1999; 58:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/51\">",
"      Beilin LJ, Burke V. Vegetarian diet components, protein and blood pressure: which nutrients are important? Clin Exp Pharmacol Physiol 1995; 22:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/52\">",
"      Snowdon DA, Phillips RL. Does a vegetarian diet reduce the occurrence of diabetes? Am J Public Health 1985; 75:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/53\">",
"      Jacobs C, Dwyer JT. Vegetarian children: appropriate and inappropriate diets. Am J Clin Nutr 1988; 48:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/54\">",
"      Ressler N. Modifying coronary heart disease risk factors in children: is it ever too early to start? JAMA 1998; 279:1261; author reply 1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/55\">",
"      Salo P, Viikari J, Rask-Nissil&auml; L, et al. Effect of low-saturated fat, low-cholesterol dietary intervention on fatty acid compositions in serum lipid fractions in 5-year-old children. The STRIP project. Eur J Clin Nutr 1999; 53:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/56\">",
"      Dwyer JT. Vegetarian eating patterns: science, values, and food choices--where do we go from here? Am J Clin Nutr 1994; 59:1255S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/57\">",
"      Messina V, Melina V, Mangels AR. A new food guide for North American vegetarians. J Am Diet Assoc 2003; 103:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/58\">",
"      Perry CL, McGuire MT, Neumark-Sztainer D, Story M. Adolescent vegetarians: how well do their dietary patterns meet the healthy people 2010 objectives? Arch Pediatr Adolesc Med 2002; 156:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/59\">",
"      Fox N, Ward KJ. You are what you eat? Vegetarianism, health and identity. Soc Sci Med 2008; 66:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/60\">",
"      Robinson-O'Brien R, Perry CL, Wall MM, et al. Adolescent and young adult vegetarianism: better dietary intake and weight outcomes but increased risk of disordered eating behaviors. J Am Diet Assoc 2009; 109:648.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. National Academies Press, Washington DC, 2005. Available at:  file://www.nap.edu/catalog.php?record_id=10490 (Accessed on December 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/62\">",
"      Larsson CL, Johansson GK. Young Swedish vegans have different sources of nutrients than young omnivores. J Am Diet Assoc 2005; 105:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/63\">",
"      Rosell MS, Lloyd-Wright Z, Appleby PN, et al. Long-chain n-3 polyunsaturated fatty acids in plasma in British meat-eating, vegetarian, and vegan men. Am J Clin Nutr 2005; 82:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/64\">",
"      Koletzko B, Beblo S, Demmelmair H, Hanebutt FL. Omega-3 LC-PUFA supply and neurological outcomes in children with phenylketonuria (PKU). J Pediatr Gastroenterol Nutr 2009; 48 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/65\">",
"      Young VR. Soy protein in relation to human protein and amino acid nutrition. J Am Diet Assoc 1991; 91:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/66\">",
"      Fomon SJ, Ziegler EE, Nelson SE, Edwards BB. Requirement for sulfur-containing amino acids in infancy. J Nutr 1986; 116:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/67\">",
"      Fomon SJ, Ziegler EE, Filer LJ Jr, et al. Methionine fortification of a soy protein formula fed to infants. Am J Clin Nutr 1979; 32:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/68\">",
"      Young VR, Pellett PL. Plant proteins in relation to human protein and amino acid nutrition. Am J Clin Nutr 1994; 59:1203S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/69\">",
"      Young VR, Wayler A, Garza C, et al. A long-term metabolic balance study in young men to assess the nutritional quality of an isolated soy protein and beef proteins. Am J Clin Nutr 1984; 39:8.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston PK, Sabate, J. Nutritional implications of vegetarian diets. In: Modern nutrition in health and disease, 10 Ed, Shils ME, Shike M, Ross, AC, et al (Eds), Lippincott Williams &amp; Wilkins, Baltiomore 2006. p.1641.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/71\">",
"      Thane CW, Bates CJ, Prentice A. Risk factors for low iron intake and poor iron status in a national sample of British young people aged 4-18 years. Public Health Nutr 2003; 6:485.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Available at:  file://www.nap.edu/catalog.php?record_id=10026 (Accessed on December 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/73\">",
"      Fairweather-Tait S, Hurrell RF. Bioavailability of minerals and trace elements. Nutr Res Rev 1996; 9:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/74\">",
"      Roughead ZK, Hunt JR. Adaptation in iron absorption: iron supplementation reduces nonheme-iron but not heme-iron absorption from food. Am J Clin Nutr 2000; 72:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/75\">",
"      Disler PB, Lynch SR, Charlton RW, et al. The effect of tea on iron absorption. Gut 1975; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/76\">",
"      Hallberg L, Hulth&eacute;n L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr 2000; 71:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/77\">",
"      Hallberg L, Rossander L, Sk&aring;nberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nutr 1987; 45:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/78\">",
"      Hunt JR. Bioavailability of iron, zinc, and other trace minerals from vegetarian diets. Am J Clin Nutr 2003; 78:633S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/79\">",
"      Craig WJ. Iron status of vegetarians. Am J Clin Nutr 1994; 59:1233S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/80\">",
"      Donovan UM, Gibson RS. Iron and zinc status of young women aged 14 to 19 years consuming vegetarian and omnivorous diets. J Am Coll Nutr 1995; 14:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/81\">",
"      Dwyer JT, Dietz WH Jr, Andrews EM, Suskind RM. Nutritional status of vegetarian children. Am J Clin Nutr 1982; 35:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/82\">",
"      Lynch SR. Interaction of iron with other nutrients. Nutr Rev 1997; 55:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/83\">",
"      Gibson SA. Iron intake and iron status of preschool children: associations with breakfast cereals, vitamin C and meat. Public Health Nutr 1999; 2:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/84\">",
"      Soh P, Ferguson EL, McKenzie JE, et al. Dietary intakes of 6-24-month-old urban South Island New Zealand children in relation to biochemical iron status. Public Health Nutr 2002; 5:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/85\">",
"      Chiplonkar SA, Tupe R. Development of a diet quality index with special reference to micronutrient adequacy for adolescent girls consuming a lacto-vegetarian diet. J Am Diet Assoc 2010; 110:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/86\">",
"      Hallberg L, Brune M, Rossander L. Effect of ascorbic acid on iron absorption from different types of meals. Studies with ascorbic-acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. Hum Nutr Appl Nutr 1986; 40:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/87\">",
"      Siegenberg D, Baynes RD, Bothwell TH, et al. Ascorbic acid prevents the dose-dependent inhibitory effects of polyphenols and phytates on nonheme-iron absorption. Am J Clin Nutr 1991; 53:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/88\">",
"      Sandstr&ouml;m B. Micronutrient interactions: effects on absorption and bioavailability. Br J Nutr 2001; 85 Suppl 2:S181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/89\">",
"      Anderson GH, Zlotkin SH. Developing and implementing food-based dietary guidance for fat in the diets of children. Am J Clin Nutr 2000; 72:1404S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/90\">",
"      Harland BF, Morris ER. Phytate: a good or a bad food component? Nutr Res 1995; 15:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/91\">",
"      Gibson RS, Hotz C. Dietary diversification/modification strategies to enhance micronutrient content and bioavailability of diets in developing countries. Br J Nutr 2001; 85 Suppl 2:S159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/92\">",
"      Hunt JR. Moving toward a plant-based diet: are iron and zinc at risk? Nutr Rev 2002; 60:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/93\">",
"      Haddad EH. Development of a vegetarian food guide. Am J Clin Nutr 1994; 59:1248S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/94\">",
"      Matkovic V, Fontana D, Tominac C, et al. Factors that influence peak bone mass formation: a study of calcium balance and the inheritance of bone mass in adolescent females. Am J Clin Nutr 1990; 52:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/95\">",
"      Matkovic V, Heaney RP. Calcium balance during human growth: evidence for threshold behavior. Am J Clin Nutr 1992; 55:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/96\">",
"      Weaver CM, Proulx WR, Heaney R. Choices for achieving adequate dietary calcium with a vegetarian diet. Am J Clin Nutr 1999; 70:543S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/97\">",
"      Greer FR, Krebs NF, American Academy of Pediatrics Committee on Nutrition. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006; 117:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/98\">",
"      Heaney RP. Protein intake and the calcium economy. J Am Diet Assoc 1993; 93:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/99\">",
"      Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/100\">",
"      Tayter M, Stanek KL. Anthropometric and dietary assessment of omnivore and lacto-ovo-vegetarian children. J Am Diet Assoc 1989; 89:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/101\">",
"      Donovan UM, Gibson RS. Dietary intakes of adolescent females consuming vegetarian, semi-vegetarian, and omnivorous diets. J Adolesc Health 1996; 18:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/102\">",
"      Sanders TA. Vegetarian diets and children. Pediatr Clin North Am 1995; 42:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/103\">",
"      Tesar R, Notelovitz M, Shim E, et al. Axial and peripheral bone density and nutrient intakes of postmenopausal vegetarian and omnivorous women. Am J Clin Nutr 1992; 56:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/104\">",
"      Dagnelie PC, van Dusseldorp M, van Staveren WA, Hautvast JG. Effects of macrobiotic diets on linear growth in infants and children until 10 years of age. Eur J Clin Nutr 1994; 48 Suppl 1:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/105\">",
"      Haddad EH. Meeting the RDAs with a vegetarian diet. Top Clin Nutr 1995; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/106\">",
"      Heaney RP, Dowell MS, Rafferty K, Bierman J. Bioavailability of the calcium in fortified soy imitation milk, with some observations on method. Am J Clin Nutr 2000; 71:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/107\">",
"      Bonjour JP, Carrie AL, Ferrari S, et al. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 1997; 99:1287.",
"     </a>",
"    </li>",
"    <li>",
"     Dietary supplement fact sheet: vitamin D. Office of Dietary Supplements, National Institute of Health, Bethesda, MD, 2008 file://ods.od.nih.gov/factsheets/vitamind.asp (Accessed on March 24, 2009).",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. National Academy Press, Washington DC, 2010. Available at:  file://books.nap.edu/openbook.php?record_id=13050.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/110\">",
"      Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/111\">",
"      Bergstrom WH. When you see rickets, consider calcium deficiency. J Pediatr 1998; 133:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/112\">",
"      Dwyer JT, Dietz WH Jr, Hass G, Suskind R. Risk of nutritional rickets among vegetarian children. Am J Dis Child 1979; 133:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/113\">",
"      Hellebostad M, Markestad T, Seeger Halvorsen K. Vitamin D deficiency rickets and vitamin B12 deficiency in vegetarian children. Acta Paediatr Scand 1985; 74:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/114\">",
"      Parsons TJ, van Dusseldorp M, van der Vliet M, et al. Reduced bone mass in Dutch adolescents fed a macrobiotic diet in early life. J Bone Miner Res 1997; 12:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/115\">",
"      Dagnelie PC, Vergote FJ, van Staveren WA, et al. High prevalence of rickets in infants on macrobiotic diets. Am J Clin Nutr 1990; 51:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/116\">",
"      Herrmann W, Geisel J. Vegetarian lifestyle and monitoring of vitamin B-12 status. Clin Chim Acta 2002; 326:47.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline, National Academy Press, Washington DC, 1998. Available at:  file://www.nap.edu/catalog.php?record_id=6015 (Accessed on December 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/118\">",
"      Krajcovicov&aacute;-Kudl&aacute;ckov&aacute; M, Blaz&iacute;cek P, Kopcov&aacute; J, et al. Homocysteine levels in vegetarians versus omnivores. Ann Nutr Metab 2000; 44:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/119\">",
"      Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull 2008; 29:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/120\">",
"      Haddad EH, Berk LS, Kettering JD, et al. Dietary intake and biochemical, hematologic, and immune status of vegans compared with nonvegetarians. Am J Clin Nutr 1999; 70:586S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/121\">",
"      Dong A, Scott SC. Serum vitamin B12 and blood cell values in vegetarians. Ann Nutr Metab 1982; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/122\">",
"      Dagnelie PC, van Staveren WA, van den Berg H. Vitamin B-12 from algae appears not to be bioavailable. Am J Clin Nutr 1991; 53:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/123\">",
"      Burke KI. The use of soy foods in a vegetarian diet. Top Clin Nutr 1995; 10:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/124\">",
"      Davies GJ, Crowder M, Dickerson JW. Dietary fibre intakes of individuals with different eating patterns. Hum Nutr Appl Nutr 1985; 39:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/125\">",
"      Dagnelie PC, van Staveren WA, Hautvast JG. Stunting and nutrient deficiencies in children on alternative diets. Acta Paediatr Scand Suppl 1991; 374:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/126\">",
"      Williams CL, Bollella M. Is a high-fiber diet safe for children? Pediatrics 1995; 96:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/127\">",
"      Agostoni C, Riva E, Giovannini M. Dietary fiber in weaning foods of young children. Pediatrics 1995; 96:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/128\">",
"      Davidsson L, Mackenzie J, Kastenmayer P, et al. Dietary fiber in weaning cereals: a study of the effect on stool characteristics and absorption of energy, nitrogen, and minerals in healthy infants. J Pediatr Gastroenterol Nutr 1996; 22:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/129\">",
"      Dagnelie PC, van Staveren WA. Macrobiotic nutrition and child health: results of a population-based, mixed-longitudinal cohort study in The Netherlands. Am J Clin Nutr 1994; 59:1187S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/4/8266/abstract/130\">",
"      Amit M. Vegetarian diets in children and adolescents. Paediatr Child Health 2010; 15:303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5353 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8266=[""].join("\n");
var outline_f8_4_8266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF VEGETARIAN DIETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GROWTH OF VEGETARIAN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NUTRITIONAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Eating disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Energy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Amino acid composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Digestibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Zinc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vitamin B12",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fiber",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6020875\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5353|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/29/25053\" title=\"figure 1\">",
"      Protein intake and stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/23/20862\" title=\"figure 2\">",
"      Vit D metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5353|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/45/9942\" title=\"picture 1\">",
"      Macroovalocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/5/26715\" title=\"table 1\">",
"      Iron bioavailability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/22/38241\" title=\"table 2\">",
"      DRI trace elements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/25/35229\" title=\"table 3\">",
"      Dietary sources of absorbable calcium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=related_link\">",
"      Calcium requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23735?source=related_link\">",
"      Dietary energy requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_4_8267="DDx medial elbow injury";
var content_f8_4_8267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Most common medial elbow throwing injury by skeletal maturity level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Maturity level",
"       </td>",
"       <td class=\"subtitle1\">",
"        Skeletal maturity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Childhood",
"       </td>",
"       <td>",
"        From birth to the appearance of all secondary ossification centers",
"       </td>",
"       <td>",
"        Medial epcondyle apophysitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adolescence",
"       </td>",
"       <td>",
"        From the appearance of all to the fusion of all the secondary ossification centers",
"       </td>",
"       <td>",
"        Medial epicondyle avulsion fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Young adulthood",
"       </td>",
"       <td>",
"        From the end of adolescence to the attainment of all bone growth and muscular form",
"       </td>",
"       <td>",
"        Ulnar collateral ligament tear",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8267=[""].join("\n");
var outline_f8_4_8267=null;
var title_f8_4_8268="Single gene defects associated with obesity";
var content_f8_4_8268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Single gene defects associated with obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Single gene disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptin deficiency",
"        <em>",
"         (LEP)",
"        </em>",
"       </td>",
"       <td>",
"        7q31.3",
"       </td>",
"       <td>",
"        Severe, early onset obesity, hypometabolic rate, hyperphagia, pubertal delay, impaired glucose tolerance, hypothalamic hypogonadism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pro-opiomelanocortin&nbsp;deficiency",
"        <em>",
"         (POMC)",
"        </em>",
"       </td>",
"       <td>",
"        2p23.3",
"       </td>",
"       <td>",
"        Severe, early onset obesity, red hair, hyperphagia, adrenal insufficiency, hyperpigmentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proprotein convertase 1 (",
"        <em>",
"         PCSK1",
"        </em>",
"        , also&nbsp;known as prohormone convertase 1)",
"       </td>",
"       <td>",
"        5q15-q21",
"       </td>",
"       <td>",
"        Early onset obesity, abnormal glucose homeostasis, hypogonadotropic hypogonadism, hypocortisolism, elevated plasma proinsulin and POMC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanocortin receptor 4 haploinsufficiency",
"        <em>",
"         (MC4R)",
"        </em>",
"       </td>",
"       <td>",
"        18q21.3-q22",
"       </td>",
"       <td>",
"        Early onset, moderate-severe obesity, early onset hyperphagia, increased bone density",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptin receptor deficiency",
"        <em>",
"         (LEPR)",
"        </em>",
"       </td>",
"       <td>",
"        1p31-p22",
"       </td>",
"       <td>",
"        Severe, early onset obesity, hypometabolic rate, hyperphagia, pubertal delay, hypothalamic hypogonadism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <ol>",
"      <li>",
"       Hoppin AG. Obesity. In: Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis and Management, 4th ed, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, Ontario, 2004. p. 311",
"      </li>",
"      <li>",
"       Leibel RL, Chua SC, Rosenbaum M. Obesity. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p. 3965.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8268=[""].join("\n");
var outline_f8_4_8268=null;
var title_f8_4_8269="Herbal medicine hepatotoxicity";
var content_f8_4_8269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some of the herbal supplements associated with hepatic injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Product",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other names/toxins",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathologic findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Chaparral leaf",
"       </td>",
"       <td>",
"        Laurie tridentata",
"       </td>",
"       <td rowspan=\"4\">",
"        ALT 10-20x normal; AST 7-10x normal; elevated bilirubin and prothrombin time; reversible; dose dependent",
"       </td>",
"       <td rowspan=\"4\">",
"        Acute and chronic liver injury: portal inflammation with bile duct proliferation; lobular necrosis and collapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Creosote bush\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Grease wood\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nordi-hydroguaiaretic acid (HDGA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Jin Bu Huan",
"       </td>",
"       <td>",
"        Lycopodium serratum",
"       </td>",
"       <td rowspan=\"2\">",
"        ALT/AST 10-20x normal; elevated bilirubin and prothrombin time; reversible",
"       </td>",
"       <td rowspan=\"2\">",
"        Acute and chronic liver injury: focal hepatic necrosis; eosinophilia; steatosis; bridging fibrosis and necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levo-tetrahydropalmatine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Germander",
"       </td>",
"       <td>",
"        Teucrium chamaedrys",
"       </td>",
"       <td rowspan=\"2\">",
"        ALT/AST 5-10x normal; elevated bilirubin; reversible",
"       </td>",
"       <td rowspan=\"2\">",
"        Acute and chronic liver injury: hepatocellular necrosis; portal inflammation; fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teucrium polium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kava",
"       </td>",
"       <td>",
"        Piper methysticum rhizoma",
"       </td>",
"       <td>",
"        ALT/AST 10-20X normal; elevated bilirubin, prothrombin time; can be fatal",
"       </td>",
"       <td>",
"        Hepatic necrosis; cholestasis, lobular hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mistletoe",
"       </td>",
"       <td>",
"        Viscum album",
"       </td>",
"       <td>",
"        ALT/AST 5-10x normal; elevated bilirubin; reversible",
"       </td>",
"       <td>",
"        Acute and chronic hepatitis: hepatocellular injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skullcap",
"       </td>",
"       <td>",
"        Scutellaria sp.",
"       </td>",
"       <td>",
"        ALT/AST 5-10x normal; elevated bilirubin; reversible",
"       </td>",
"       <td>",
"        Acute hepatitis; hepatocellular injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        Toxic alkaloids",
"       </td>",
"       <td>",
"        Symphytum (Comfrey)",
"       </td>",
"       <td rowspan=\"12\">",
"        ALT/AST 3-10x normal; elevated bilirubin; generally reversible; can be fatal; dose dependent",
"       </td>",
"       <td rowspan=\"12\">",
"        Hepatic venoocclusive disease; acute inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Senecio sp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crotalaria sp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heliotropium sp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mat&eacute; (Paraquay) tea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ackee Fruit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atractylis gummifera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Callilepsis laureola",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cassia angustifolia (Senna)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine (Erythroxylon coca)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sassafras albidum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Borago officinalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Pennyroyal&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        Squawmint oil",
"       </td>",
"       <td rowspan=\"4\">",
"        ALT/AST 10-20x normal; associated with renal failure",
"       </td>",
"       <td rowspan=\"4\">",
"        Acute liver injury related to depletion of hepatic glutathione",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hedeoma pulegoides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mentha pulegium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxic terpenes, especially isopropylidene",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bashir RM,&nbsp;Lewis JH. Gastroenterol Clin North Am 1995; 24:957.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8269=[""].join("\n");
var outline_f8_4_8269=null;
var title_f8_4_8270="Differential diagnosis of limp in children";
var content_f8_4_8270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abnormalities causing limp in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Osseous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteomyelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Fractures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Salter-Harris",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Toddler's: tibia, calcaneus, cuboid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stress",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Incomplete: buckle, greenstick",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Complete",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Plastic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Avulsion: pelvic, tibial tuberosity, patellar sleeve",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Child abuse: traumatic periostitis, metaphyseal-epiphyseal fracture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Apophysitis (formerly, osteochondrosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sinding-Larsen-Johansson disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            K&ouml;hler disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sever disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Freiberg disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Osgood-Schlatter disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vasoocclusive crisis of sickle cell disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Slipped capital femoral epiphysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Legg-Calv&eacute;-Perthes disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Spinal cord tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Metastatic neuroblastoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Osteogenic sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ewings sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Osteoid osteoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Articular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Transient synovitis of the hip",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Septic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteochodritis dissecans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute rheumatic fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Juvenile idiopathic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Henoch-Sch&ouml;nlein purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Serum sickness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Discitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Developmental dysplasia of the hip",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chrodomalacia of the patella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemarthrosis: traumatic, hemophilia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Patellar dislocation",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Soft tissue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Contusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Muscle strain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sprain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tendonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Viral myositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Foreign body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benign hypermobility syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intramuscular vaccination",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bursitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cellulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Baker's cyst rupture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Soft tissue abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyomyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insect envenomation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bunion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ingrown toenail",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Plantar warts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myositis ossificans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurological",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebral palsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peripheral neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epidural abscess of the spine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Complex regional pain syndrome (reflex sympathetic dystrophy)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinal cord tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Intra-abdominal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pelvic inflammatory disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pelvic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psoas abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Perirectal abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iliac adenitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Conversion disorder",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8270=[""].join("\n");
var outline_f8_4_8270=null;
var title_f8_4_8271="Treatment NTM children";
var content_f8_4_8271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doses and common adverse effects of medications used to treat nontuberculous mycobacterial (atypical mycobacterial) infections in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual maximum daily dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential adverse effects and target dose ranges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         15 to 30 mg/kg per day divided in three doses",
"         <strong>",
"          or",
"         </strong>",
"         15 to 20 mg/kg once daily&nbsp;for daily dosing;",
"        </p>",
"        <p>",
"         25 mg/kg per day in one dose for three times per week dosing",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        IV, IM",
"       </td>",
"       <td>",
"        1.5 g/day",
"       </td>",
"       <td>",
"        <p>",
"         Dizziness, ataxia, vertigo, tinnitus, hearing loss, nephrotoxicity",
"        </p>",
"        <p>",
"         For every 8 hour dosing*: Adjust&nbsp;dose for trough &lt;3 to 5 mcg/mL and&nbsp;peak 20 to 25 mcg/mL",
"        </p>",
"        <p>",
"         For&nbsp;once daily dosing*: Adjust dose for trough 0.5 to 1 mcg/mL (at 18 hours) and peak 40 to 50 mcg/mL&nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin",
"       </td>",
"       <td>",
"        <p>",
"         5 to 12 mg/kg per day in one dose for daily dosing;",
"        </p>",
"        <p>",
"         10 mg/kg per day in one dose for three times per week dosing",
"        </p>",
"       </td>",
"       <td>",
"        Oral, IV",
"       </td>",
"       <td>",
"        <p>",
"         Oral: 600 mg/day",
"        </p>",
"        <p>",
"         IV: 500 mg/day",
"        </p>",
"       </td>",
"       <td>",
"        Prolongation of the QT interval, nausea vomiting, diarrhea, decreased hearing, dizziness,&nbsp;hepatitis, phlebitis (IV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefoxitin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        160 mg/kg per day divided in four doses",
"       </td>",
"       <td>",
"        IV, IM",
"       </td>",
"       <td>",
"        12 g/day",
"       </td>",
"       <td>",
"        Bone marrow suppression, interstitial nephritis, hypersensitivity (fever, rash),&nbsp;may&nbsp;interfere with&nbsp;serum creatinine assay (falsely elevates creatinine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        20 mg/kg per day divided in two doses",
"       </td>",
"       <td>",
"        Oral, IV",
"       </td>",
"       <td>",
"        <p>",
"         Oral: 1.5 g/day",
"        </p>",
"        <p>",
"         IV: 800 mg/day",
"        </p>",
"       </td>",
"       <td>",
"        Tendon damage, prolongation of the QT interval, central nervous system stimulation, nausea, vomiting, diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        15 to 30 mg/kg per day divided in two doses (for daily or three times per week dosing)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        1 g/day",
"       </td>",
"       <td>",
"        Prolongation of the QT interval, nausea vomiting, diarrhea, taste disturbance,&nbsp;decreased hearing, hepatitis",
"        <sup>",
"         &loz;",
"        </sup>",
"        , anterior uveitis",
"        <sup>",
"         &loz;",
"        </sup>",
"        , arthralgia",
"        <sup>",
"         &loz;",
"        </sup>",
"        , granulocytopenia",
"        <sup>",
"         &loz;",
"        </sup>",
"        , significant drug-drug interactions (particularly with rifamycins)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline",
"       </td>",
"       <td>",
"        2 to 4 mg/kg per day in one or two doses",
"       </td>",
"       <td>",
"        Oral, IV",
"       </td>",
"       <td>",
"        200 mg/day",
"       </td>",
"       <td>",
"        Tooth discoloration in children &lt;8 years, nausea, vomiting, diarrhea, photosensitivity, rash, hyperpigmentation, phlebitis (IV),&nbsp;and injection site pain (IV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethambutol",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         15 mg/kg per day in one dose for daily dosing;",
"        </p>",
"        <p>",
"         25 mg/kg per day in one dose for three times per week dosing",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        2.5 g/day",
"       </td>",
"       <td>",
"        Optic neuritis (usually reversible)",
"        <sup>",
"         &sect;",
"        </sup>",
"        , red-green color blindness",
"        <sup>",
"         &yen;",
"        </sup>",
"        , gastrointestinal disturbances, hypersensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoniazid",
"       </td>",
"       <td>",
"        <p>",
"         5 mg/kg per day for NTM infection;",
"        </p>",
"        <p>",
"         10 to 15",
"         <sup>",
"          ",
"         </sup>",
"         mg/kg per day in one dose if cannot definitively exclude",
"         <em>",
"          M. tuberculosis",
"         </em>",
"        </p>",
"       </td>",
"       <td>",
"        Oral, IM",
"       </td>",
"       <td>",
"        300 mg/day",
"       </td>",
"       <td>",
"        <p>",
"         Mild hepatic enzyme elevation, hepatitis",
"         <sup>",
"          ",
"         </sup>",
"         , peripheral neuritis, hypersensitivity (fever, rash), diarrhea and gastric irritation (caused by vehicle in syrup)",
"        </p>",
"        <p>",
"         Pyridoxine supplementation of 1 to 2 mg/kg per day (up to 50 mg/day) is suggested to prevent peripheral neuropathy in exclusively breastfed infants; children and adolescents on meat- and milk-deficient diets; children with nutritional deficiencies; children and adolescents with symptomatic HIV infection, and pregnant adolescents",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levofloxacin",
"        <sup>",
"         &bull;&nbsp;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         &lt;5 years: 20 mg/kg per day in two doses;",
"        </p>",
"        <p>",
"         &ge;5 years: 10 mg/kg once daily",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;Oral, IV",
"       </td>",
"       <td>",
"        <p>",
"         500&nbsp;mg/day",
"        </p>",
"       </td>",
"       <td>",
"        Tendon damage, central nervous system stimulation, nausea, vomiting, diarrhea&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linezolid",
"       </td>",
"       <td>",
"        <p>",
"         &lt;12 years: 30 mg/kg per day in three doses;",
"        </p>",
"        &ge;12 years: 600 mg twice per day",
"       </td>",
"       <td>",
"        Oral, IV",
"       </td>",
"       <td>",
"        <p>",
"         1200 mg/day",
"        </p>",
"       </td>",
"       <td>",
"        Nausea, vomiting, diarrhea, leukopenia, anemia, thrombocytopenia, pancytopenia, peripheral neuropathy, optic neuritis, serotonin syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         &lt;50 kg: 30 to 60 mg/kg per day divided in three doses;",
"        </p>",
"        <p>",
"         &ge;50 kg 3 g/day in three divided doses",
"        </p>",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        3&nbsp;g/day",
"       </td>",
"       <td>",
"        May lower seizure threshold, bone marrow suppression, interstitial nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        <p>",
"         400 mg per day&nbsp;in one dose",
"        </p>",
"        <p>",
"         (for adolescents)",
"        </p>",
"       </td>",
"       <td>",
"        Oral&nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         &nbsp;400 mg/day",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        Tendon damage, central nervous system stimulation, nausea, vomiting, diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifabutin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        10 to 20 mg/kg per day in one dose (for daily or three times per week dosing)",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        300 mg/day",
"       </td>",
"       <td>",
"        Orange discoloration of secretions (may stain soft contact lenses), urine and stool, gastrointestinal disturbance, hepatitis",
"        <sup>",
"         &loz;",
"        </sup>",
"        , \"flu-like\" syndrome, thrombocytopenia, renal failure, myalgia, arthralgia",
"        <sup>",
"         &loz;",
"        </sup>",
"        , granulocytopenia",
"        <sup>",
"         &loz;",
"        </sup>",
"        , anterior uveitis",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin (rifampicin)",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        10 to&nbsp;20 mg/kg per day in one dose (for daily or three times per week dosing)",
"       </td>",
"       <td>",
"        Oral, IV",
"       </td>",
"       <td>",
"        600 mg/day",
"       </td>",
"       <td>",
"        Orange discoloration of secretions (may stain soft contact lenses), urine and stool, gastrointestinal disturbance, hepatitis, \"flu-like\" syndrome, thrombocytopenia, renal failure, multiple significant drug-drug interactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptomycin*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        15&nbsp;to 40 mg/kg per day in one dose or in two divided doses (preferred for IV)",
"       </td>",
"       <td>",
"        IM, IV (if IM not tolerated)",
"       </td>",
"       <td>",
"        1 g/day",
"       </td>",
"       <td>",
"        <p>",
"         Dizziness, ataxia, vertigo, tinnitus, hearing loss, nephrotoxicity, hypersensitivity reaction",
"        </p>",
"        <p>",
"         Adjust dose for trough &lt;3 to 5 mcg/mL and&nbsp;peak 15 to&nbsp;30 mcg/mL for every 12 hour dosing*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobramycin*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        7.5 mg/kg per day in three doses or 7 mg/kg once daily",
"       </td>",
"       <td>",
"        IM, IV",
"       </td>",
"       <td>",
"        300 mg/day",
"       </td>",
"       <td>",
"        <p>",
"         Dizziness, ataxia, vertigo, tinnitus, hearing loss, nephrotoxicity",
"        </p>",
"        <p>",
"         For every 8 hour dosing*: Adjust dose for trough &lt;1 mcg/mL and&nbsp;peak 6 to 8 mcg/mL",
"        </p>",
"        <p>",
"         For once daily dosing*: Adjust dose for trough &lt;1 mcg/mL at 18 hours and peak 15 to 22 mcg/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"        <sup>",
"         &bull;",
"        </sup>",
"        (TMP-SMX, cotrimoxazole)",
"       </td>",
"       <td>",
"        8 to 12 mg/kg per day of the TMP component divided in two doses",
"       </td>",
"       <td>",
"        Oral, IV",
"       </td>",
"       <td>",
"        320 mg/day of TMP component",
"       </td>",
"       <td>",
"        Rash, hypersensitivity reaction (fever, rash, Stevens-Johnson syndrome), bone marrow suppression, nausea, vomiting, diarrhea, IV formulation requires substantial dilution, which may result in large volumes (which may be problematic for patients with renal insufficiency or fluid overload)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Combinations of two to four of the above agents are selected based upon type of NTM infection and susceptibility testing.&nbsp;Consultation with a specialist in infectious diseases may be warranted. (Please refer to UpToDate&nbsp;topics on NTM infections in children.)",
"    <div class=\"footnotes\">",
"     NTM: nontuberculous mycobacterial infection (also known as atypical mycobacterial infection); IV: intravenous; IM: intramuscular.",
"     <br>",
"      * Monitor drug levels to ensure efficacy and avoid toxicity. The targeted range varies depending upon the clinical syndrome, patient characteristics (eg, cystic fibrosis), and the institution. Consultation with an infectious diseases specialist or pharmacist regarding the appropriate therapeutic range is suggested. Aminoglycoside toxicity is dependent upon duration of treatment and aminoglycoside-free period of dosing interval.&nbsp;(Refer to UpToDate topic on aminoglycosides.)",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Doses are for children with normal renal function.",
"       <br>",
"        &Delta; Clinical data in adults indicate that three-times-weekly therapy is as effective as daily therapy, with reduced toxicity,&nbsp;for mild to moderate disease.&nbsp;&nbsp;",
"        <br>",
"         &loz; Anterior uveitis, arthralgia, neutropenia, and liver function abnormalities may occur when clarithromycin is used in combination with rifabutin.",
"         <br>",
"          &sect;&nbsp;Usually reversible; rare at doses of 15 to 25 mg/kg in children with normal renal function.",
"          <br>",
"           &yen;&nbsp;Rarely occurs in children who metabolize ethambutol more rapidly than adults.",
"           <br>",
"            &Dagger;&nbsp;The incidence of hepatotoxicity may be increased when isoniazid doses &gt;10 mg/kg are used in combination with rifampin.",
"            <br>",
"             &dagger;&nbsp;Dose may require modification based upon drug-drug interactions, particularly with clarithromycin.",
"             <br/>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        American Academy of Pediatrics. Tables of antimicrobial drug dosages. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.807.",
"       </li>",
"       <li>",
"        American Academy of Pediatrics. Tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.736.",
"       </li>",
"       <li>",
"        Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis 2006; 10:1318.",
"       </li>",
"       <li>",
"        Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"       </li>",
"       <li>",
"        Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58:1.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_4_8271=[""].join("\n");
var outline_f8_4_8271=null;
